JP4409938B2 - アザインドール - Google Patents
アザインドール Download PDFInfo
- Publication number
- JP4409938B2 JP4409938B2 JP2003507091A JP2003507091A JP4409938B2 JP 4409938 B2 JP4409938 B2 JP 4409938B2 JP 2003507091 A JP2003507091 A JP 2003507091A JP 2003507091 A JP2003507091 A JP 2003507091A JP 4409938 B2 JP4409938 B2 JP 4409938B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- methyl
- indol
- methoxy
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 471
- -1 methoxy, 4-fluorophenyl Chemical group 0.000 claims description 274
- 150000003839 salts Chemical class 0.000 claims description 72
- 229910052739 hydrogen Inorganic materials 0.000 claims description 70
- 239000001257 hydrogen Substances 0.000 claims description 56
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 49
- 150000001204 N-oxides Chemical class 0.000 claims description 44
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 42
- 239000012453 solvate Substances 0.000 claims description 38
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 26
- 150000004677 hydrates Chemical class 0.000 claims description 24
- 125000001041 indolyl group Chemical group 0.000 claims description 21
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 claims description 20
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- XCLJFTFBHKDRHP-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylic acid Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(O)=O XCLJFTFBHKDRHP-UHFFFAOYSA-N 0.000 claims description 10
- LIZDNKRMTCXMAV-UHFFFAOYSA-N 3-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-2-yl]-1-methylindole-5-carboxylic acid Chemical compound CC1=NOC(C)=C1C1=CC=NC2=C1C=C(C=1C3=CC(=CC=C3N(C)C=1)C(O)=O)N2 LIZDNKRMTCXMAV-UHFFFAOYSA-N 0.000 claims description 8
- CBSWBKLIQDUSCA-UHFFFAOYSA-N 3-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-1h-pyrrolo[2,3-b]pyridin-2-yl]-1h-indole-5-carboxylic acid Chemical compound CC1=NOC(C)=C1C1=CC=NC2=C1C=C(C=1C3=CC(=CC=C3NC=1)C(O)=O)N2 CBSWBKLIQDUSCA-UHFFFAOYSA-N 0.000 claims description 8
- CYGVUQDIFRECJA-UHFFFAOYSA-N 4-[2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]-3,5-dimethyl-1,2-oxazole Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2C=1C(C)=NOC=1C CYGVUQDIFRECJA-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- AMECZOITPGYJEM-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(=O)NC(C)(C)CO AMECZOITPGYJEM-UHFFFAOYSA-N 0.000 claims description 6
- JJTVNLBIXOXIQR-UHFFFAOYSA-N 4-[2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]-3,5-dimethyl-1,2-oxazole Chemical compound C12=CC(OC)=CC=C2NC=C1C(NC1=NC=C2)=CC1=C2C=1C(C)=NOC=1C JJTVNLBIXOXIQR-UHFFFAOYSA-N 0.000 claims description 5
- QPQYJHKPANJWSN-UHFFFAOYSA-N 2-(1-ethyl-5-methoxyindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylic acid Chemical compound C12=CC(OC)=CC=C2N(CC)C=C1C1=CC2=C(C(O)=O)C=CN=C2N1 QPQYJHKPANJWSN-UHFFFAOYSA-N 0.000 claims description 4
- QYYUOCTXNHRPHN-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-(2-methoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=CC=C1OC QYYUOCTXNHRPHN-UHFFFAOYSA-N 0.000 claims description 4
- 229910014033 C-OH Inorganic materials 0.000 claims description 4
- 229910014570 C—OH Inorganic materials 0.000 claims description 4
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 4
- NZQQUAQJNADKMN-UHFFFAOYSA-N n-(2-hydroxy-2-methylpropyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(=O)NCC(C)(C)O NZQQUAQJNADKMN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
- IHMYLNCEAZWLKI-UHFFFAOYSA-N n-(2-hydroxyethyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(=O)NCCO IHMYLNCEAZWLKI-UHFFFAOYSA-N 0.000 claims description 3
- QXSNZHAWKYWAKB-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C(=O)NCC(C)O QXSNZHAWKYWAKB-UHFFFAOYSA-N 0.000 claims description 3
- PYMIITKZQGMEBF-UHFFFAOYSA-N n-(2-methoxyethyl)-2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=C(OC)C=C2C(C=3NC=4N=CC=C(C=4C=3)C(=O)NCCOC)=CNC2=C1 PYMIITKZQGMEBF-UHFFFAOYSA-N 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- LTFUDAWTAOIQCP-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-4-piperidin-1-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2N1CCCCC1 LTFUDAWTAOIQCP-UHFFFAOYSA-N 0.000 claims description 2
- YKOZAXNYUUUUGV-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-(2-methylphenyl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=CC=C1C YKOZAXNYUUUUGV-UHFFFAOYSA-N 0.000 claims description 2
- GQUOQYMVODOWJW-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-(3-methoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound COC1=CC=CC(NC=2C=3C=C(NC=3N=CC=2)C=2C3=CC(OC)=CC=C3N(C)C=2)=C1 GQUOQYMVODOWJW-UHFFFAOYSA-N 0.000 claims description 2
- HFGVNZBYHIWWFF-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-(3-methylphenyl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=CC(C)=C1 HFGVNZBYHIWWFF-UHFFFAOYSA-N 0.000 claims description 2
- PSGCOJYPJYTLMY-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-(4-methoxyphenyl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1NC1=CC=NC2=C1C=C(C=1C3=CC(OC)=CC=C3N(C)C=1)N2 PSGCOJYPJYTLMY-UHFFFAOYSA-N 0.000 claims description 2
- DEUZHMAECLRWHP-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-(4-methylphenyl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=C(C)C=C1 DEUZHMAECLRWHP-UHFFFAOYSA-N 0.000 claims description 2
- DIJJUHWPCLPQPG-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-[(4-methoxyphenyl)methyl]-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C1=CC(OC)=CC=C1CNC1=CC=NC2=C1C=C(C=1C3=CC(OC)=CC=C3N(C)C=1)N2 DIJJUHWPCLPQPG-UHFFFAOYSA-N 0.000 claims description 2
- NXWDZEUHBORAJK-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-n-phenyl-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=CC=C1 NXWDZEUHBORAJK-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims description 2
- OKGPJXPNOFADAQ-UHFFFAOYSA-N methyl 3-[[2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]amino]benzoate Chemical compound COC(=O)C1=CC=CC(NC=2C=3C=C(NC=3N=CC=2)C=2C3=CC(OC)=CC=C3N(C)C=2)=C1 OKGPJXPNOFADAQ-UHFFFAOYSA-N 0.000 claims description 2
- GATJDCDYZSCRKG-UHFFFAOYSA-N n-(2-methoxyethyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C1=C(OC)C=C2C(C=3NC=4N=CC=C(C=4C=3)NCCOC)=CN(C)C2=C1 GATJDCDYZSCRKG-UHFFFAOYSA-N 0.000 claims description 2
- VUISMYNHSHYGNC-UHFFFAOYSA-N n-(2-methoxyethyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=C(OC)C=C2C(C=3NC=4N=CC=C(C=4C=3)C(=O)NCCOC)=CN(C)C2=C1 VUISMYNHSHYGNC-UHFFFAOYSA-N 0.000 claims description 2
- SJIZNASJDWYKEO-UHFFFAOYSA-N n-(4-fluorophenyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NC1=CC=C(F)C=C1 SJIZNASJDWYKEO-UHFFFAOYSA-N 0.000 claims description 2
- BEJCDSFHBRRBCZ-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NCC1CC1 BEJCDSFHBRRBCZ-UHFFFAOYSA-N 0.000 claims description 2
- GMQQRQJKMGSYIH-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NCC1=CC=C(F)C=C1 GMQQRQJKMGSYIH-UHFFFAOYSA-N 0.000 claims description 2
- XOVQQQXEHUBONT-UHFFFAOYSA-N n-benzyl-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2NCC1=CC=CC=C1 XOVQQQXEHUBONT-UHFFFAOYSA-N 0.000 claims description 2
- BSEPLNALYMPGKA-UHFFFAOYSA-N n-butyl-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-amine Chemical compound C1=C(OC)C=C2C(C=3NC=4N=CC=C(C=4C=3)NCCCC)=CN(C)C2=C1 BSEPLNALYMPGKA-UHFFFAOYSA-N 0.000 claims description 2
- UUNAXRMDUUWYDW-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-2-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylic acid Chemical compound C1=CN=C2NC(C=3N(C)C4=CC=C(C=C4C=3)OC)=CC2=C1C(O)=O UUNAXRMDUUWYDW-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- ALLKKRMIIXGTHU-UHFFFAOYSA-N methyl 2-(5-methoxy-1-methylindol-2-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylate Chemical compound COC1=CC=C2N(C)C(C=3NC=4N=CC=C(C=4C=3)C(=O)OC)=CC2=C1 ALLKKRMIIXGTHU-UHFFFAOYSA-N 0.000 claims 1
- SUNYXEJXAYNXCL-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)-2-(5-methoxy-1-methylindol-2-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C=3N(C)C4=CC=C(C=C4C=3)OC)=CC2=C1C(=O)NC(C)(C)CO SUNYXEJXAYNXCL-UHFFFAOYSA-N 0.000 claims 1
- UVRVMAUEGHOYBX-UHFFFAOYSA-N n-(2-methoxyethyl)-2-(5-methoxy-1-methylindol-2-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound COC1=CC=C2N(C)C(C=3NC=4N=CC=C(C=4C=3)C(=O)NCCOC)=CC2=C1 UVRVMAUEGHOYBX-UHFFFAOYSA-N 0.000 claims 1
- PTRHJJHEZUMSQS-UHFFFAOYSA-N n-cyclopropylpyridine-4-carboxamide Chemical compound C=1C=NC=CC=1C(=O)NC1CC1 PTRHJJHEZUMSQS-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 364
- 239000007787 solid Substances 0.000 description 330
- 239000000047 product Substances 0.000 description 223
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 171
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 162
- 238000000034 method Methods 0.000 description 152
- 238000002844 melting Methods 0.000 description 127
- 230000008018 melting Effects 0.000 description 127
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 120
- 239000000243 solution Substances 0.000 description 116
- 125000000217 alkyl group Chemical group 0.000 description 114
- 239000000203 mixture Substances 0.000 description 112
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 86
- 229910001868 water Inorganic materials 0.000 description 81
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 69
- 125000003118 aryl group Chemical group 0.000 description 63
- 125000001072 heteroaryl group Chemical group 0.000 description 59
- 238000004128 high performance liquid chromatography Methods 0.000 description 59
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 55
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 53
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 51
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 51
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 49
- 229940002612 prodrug Drugs 0.000 description 45
- 239000000651 prodrug Substances 0.000 description 45
- 238000004809 thin layer chromatography Methods 0.000 description 44
- 238000011282 treatment Methods 0.000 description 44
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 229910005965 SO 2 Inorganic materials 0.000 description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 41
- 239000002253 acid Substances 0.000 description 38
- VAJOSPMTARTPKN-UHFFFAOYSA-N 2-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound C1=C(C=2NC3=NC=CN=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 VAJOSPMTARTPKN-UHFFFAOYSA-N 0.000 description 36
- 229910052757 nitrogen Inorganic materials 0.000 description 36
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
- 239000012442 inert solvent Substances 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 32
- 238000003756 stirring Methods 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- 239000000377 silicon dioxide Substances 0.000 description 30
- 125000004093 cyano group Chemical group *C#N 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 27
- 125000000753 cycloalkyl group Chemical group 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 26
- 125000005843 halogen group Chemical group 0.000 description 26
- 238000010992 reflux Methods 0.000 description 23
- 229910052799 carbon Inorganic materials 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 125000003342 alkenyl group Chemical group 0.000 description 21
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 21
- 239000012634 fragment Substances 0.000 description 21
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 20
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 239000002585 base Substances 0.000 description 20
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 20
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 19
- 238000003818 flash chromatography Methods 0.000 description 19
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 18
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- CVDGAVDNVQNYQT-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxylic acid Chemical compound C12=CC(C(O)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 CVDGAVDNVQNYQT-UHFFFAOYSA-N 0.000 description 17
- NCODGTKJFCNVAH-UHFFFAOYSA-N 1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxylic acid Chemical compound C12=CC(C(O)=O)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 NCODGTKJFCNVAH-UHFFFAOYSA-N 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 17
- 238000000354 decomposition reaction Methods 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 125000003545 alkoxy group Chemical group 0.000 description 16
- 150000001721 carbon Chemical group 0.000 description 16
- 239000000284 extract Substances 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 13
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 13
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 13
- 238000000921 elemental analysis Methods 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 11
- 125000006414 CCl Chemical group ClC* 0.000 description 11
- 102000004584 Somatomedin Receptors Human genes 0.000 description 11
- 108010017622 Somatomedin Receptors Proteins 0.000 description 11
- 125000003710 aryl alkyl group Chemical group 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 125000001475 halogen functional group Chemical group 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 11
- 108090000461 Aurora Kinase A Proteins 0.000 description 10
- 102100032311 Aurora kinase A Human genes 0.000 description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- 230000006978 adaptation Effects 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- MWOCLUCRSVBPPP-UHFFFAOYSA-N 4-methoxy-2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=C(OC)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 MWOCLUCRSVBPPP-UHFFFAOYSA-N 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 9
- 229910052796 boron Inorganic materials 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 229960004063 propylene glycol Drugs 0.000 description 9
- 125000000168 pyrrolyl group Chemical group 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- RVHRALDRJAGLNN-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-6-carboxylic acid Chemical compound C12=CC=C(C(O)=O)C=C2N(C)C=C1C1=CC2=CC=CN=C2N1 RVHRALDRJAGLNN-UHFFFAOYSA-N 0.000 description 8
- CHIFTAQVXHNVRW-UHFFFAOYSA-N 1h-indole-3-carbonitrile Chemical compound C1=CC=C2C(C#N)=CNC2=C1 CHIFTAQVXHNVRW-UHFFFAOYSA-N 0.000 description 8
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- BQBOHCHMCHLMDK-UHFFFAOYSA-N 3-(4-cyano-1h-pyrrolo[2,3-b]pyridin-2-yl)-1-methylindole-5-carboxylic acid Chemical compound C12=CC(C(O)=O)=CC=C2N(C)C=C1C1=CC2=C(C#N)C=CN=C2N1 BQBOHCHMCHLMDK-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- 102000001253 Protein Kinase Human genes 0.000 description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 8
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 235000019260 propionic acid Nutrition 0.000 description 8
- 108060006633 protein kinase Proteins 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- KYWSGFFFDGCSES-UHFFFAOYSA-N 1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-5-ol Chemical compound C12=CC(O)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 KYWSGFFFDGCSES-UHFFFAOYSA-N 0.000 description 7
- SWSNYMMQZWVXAI-UHFFFAOYSA-N 3-(4-chloro-1h-pyrrolo[2,3-b]pyridin-2-yl)-1-methylindole-5-carboxylic acid Chemical compound C12=CC(C(O)=O)=CC=C2N(C)C=C1C1=CC2=C(Cl)C=CN=C2N1 SWSNYMMQZWVXAI-UHFFFAOYSA-N 0.000 description 7
- NWCNXQNJIZEBTG-UHFFFAOYSA-N 3-[6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]propanoic acid Chemical compound N1C2=NC=CN=C2C(CCC(=O)O)=C1C1=CC=C(O)C=C1 NWCNXQNJIZEBTG-UHFFFAOYSA-N 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- MIJMZVTYIXYSDK-UHFFFAOYSA-N 6-(5-methoxy-1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=N1 MIJMZVTYIXYSDK-UHFFFAOYSA-N 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 239000004146 Propane-1,2-diol Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000000105 evaporative light scattering detection Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 239000012280 lithium aluminium hydride Substances 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- QSZHVPFODMPGOS-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylic acid Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1C(O)=O QSZHVPFODMPGOS-UHFFFAOYSA-N 0.000 description 6
- HQXGRCCXAAELRO-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propan-1-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCCN)C2=NC=CN=C2N1 HQXGRCCXAAELRO-UHFFFAOYSA-N 0.000 description 6
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000005973 Carvone Substances 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 125000003302 alkenyloxy group Chemical group 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- 125000005530 alkylenedioxy group Chemical group 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- KVFIJIWMDBAGDP-UHFFFAOYSA-N ethylpyrazine Chemical compound CCC1=CN=CC=N1 KVFIJIWMDBAGDP-UHFFFAOYSA-N 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- AZEKOCYKHUJNKS-UHFFFAOYSA-N 1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxycyclobutane-1-carboxylic acid Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(C(O)=O)CCC1 AZEKOCYKHUJNKS-UHFFFAOYSA-N 0.000 description 5
- RPOHBQMVRIVWKP-UHFFFAOYSA-N 1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropan-2-ol Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OCC(O)C)=CC2=C1 RPOHBQMVRIVWKP-UHFFFAOYSA-N 0.000 description 5
- VZLHVQTYCPRPHS-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1 VZLHVQTYCPRPHS-UHFFFAOYSA-N 0.000 description 5
- NUKAUWIUEJFXDV-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=C(C#N)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 NUKAUWIUEJFXDV-UHFFFAOYSA-N 0.000 description 5
- DYFHPNQRLTZBCB-UHFFFAOYSA-N 6-(4-methylsulfanylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(SC)=CC=C1C1=CC2=NC=CN=C2N1 DYFHPNQRLTZBCB-UHFFFAOYSA-N 0.000 description 5
- VWKKNDNFMQEZPN-UHFFFAOYSA-N 6-(4-piperazin-1-ylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1CNCCN1C1=CC=C(C=2NC3=NC=CN=C3C=2)C=C1 VWKKNDNFMQEZPN-UHFFFAOYSA-N 0.000 description 5
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 5
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- UGHVSNVFYBZSLH-UHFFFAOYSA-N [1-[1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-5-yl]oxycyclobutyl]methanol Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CN=C4C=3)C2=CC=1OC1(CO)CCC1 UGHVSNVFYBZSLH-UHFFFAOYSA-N 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000013066 combination product Substances 0.000 description 5
- 229940127555 combination product Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000003831 tetrazolyl group Chemical group 0.000 description 5
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 4
- QBUASRVBPRBVRJ-UHFFFAOYSA-N 1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxycyclobutane-1-carboxamide Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(C(N)=O)CCC1 QBUASRVBPRBVRJ-UHFFFAOYSA-N 0.000 description 4
- UVGZNKUGQAZSFE-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(N)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 UVGZNKUGQAZSFE-UHFFFAOYSA-N 0.000 description 4
- FBAXZPMXGBNBPE-UHFFFAOYSA-N 1-methylindole-3-carbonitrile Chemical compound C1=CC=C2N(C)C=C(C#N)C2=C1 FBAXZPMXGBNBPE-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- GZRCWJUTTURNJO-UHFFFAOYSA-N 2-(5,6-dimethoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(C)C=3)OC)OC)=CC2=C1 GZRCWJUTTURNJO-UHFFFAOYSA-N 0.000 description 4
- FTJGHPGHUSLQAK-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1C#N FTJGHPGHUSLQAK-UHFFFAOYSA-N 0.000 description 4
- CIDALPHOFCAXQR-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1C#N CIDALPHOFCAXQR-UHFFFAOYSA-N 0.000 description 4
- JODRAEBPOHRJGI-UHFFFAOYSA-N 2-[1-methyl-5-(2h-tetrazol-5-yl)indol-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1C=1N=NNN=1 JODRAEBPOHRJGI-UHFFFAOYSA-N 0.000 description 4
- BVYQFCOYMRAQQN-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetic acid Chemical compound C1=CN=C2NC(C3=CN(CC(O)=O)C4=CC=C(C=C43)OC)=CC2=C1 BVYQFCOYMRAQQN-UHFFFAOYSA-N 0.000 description 4
- WSECXIQXQRTLLK-UHFFFAOYSA-N 3-(4-cyano-1h-pyrrolo[2,3-b]pyridin-2-yl)-n-(2-hydroxy-2-methylpropyl)-1-methylindole-5-carboxamide Chemical compound C12=CC(C(=O)NCC(C)(C)O)=CC=C2N(C)C=C1C1=CC2=C(C#N)C=CN=C2N1 WSECXIQXQRTLLK-UHFFFAOYSA-N 0.000 description 4
- VEKQEFMQDFQZSJ-UHFFFAOYSA-N 3-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propan-1-ol Chemical compound C12=CC=CC=C2N(CCCO)C=C1C1=CC2=NC=CN=C2N1 VEKQEFMQDFQZSJ-UHFFFAOYSA-N 0.000 description 4
- BSONOAQXFAIGPB-UHFFFAOYSA-N 3-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propan-1-ol Chemical compound C1=CN=C2NC(C3=CN(CCCO)C4=CC=C(C=C43)OC)=CC2=N1 BSONOAQXFAIGPB-UHFFFAOYSA-N 0.000 description 4
- YHKXZXWIOPNPDS-UHFFFAOYSA-N 3-[[1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carbonyl]amino]propanoic acid Chemical compound C12=CC(C(=O)NCCC(O)=O)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 YHKXZXWIOPNPDS-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- PAWSEASAGCSQHU-UHFFFAOYSA-N 4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)aniline Chemical compound C1=CC(N)=CC=C1C1=CC2=NC=CN=C2N1 PAWSEASAGCSQHU-UHFFFAOYSA-N 0.000 description 4
- AZZIWMRQTCNYEQ-UHFFFAOYSA-N 4-chloro-2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1Cl AZZIWMRQTCNYEQ-UHFFFAOYSA-N 0.000 description 4
- QFSGJFOPYOPYRB-UHFFFAOYSA-N 4-methoxy-2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1OC QFSGJFOPYOPYRB-UHFFFAOYSA-N 0.000 description 4
- GUFVOCJZEINPME-UHFFFAOYSA-N 6-(1-benzyl-5-methoxyindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(C=2NC3=NC=CN=C3C=2)C2=CC(OC)=CC=C2N1CC1=CC=CC=C1 GUFVOCJZEINPME-UHFFFAOYSA-N 0.000 description 4
- OPIPFYKXYNLMGL-UHFFFAOYSA-N 6-(1-methyl-4-phenylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C=1N(C)C=C(C=2NC3=NC=CN=C3C=2)C=1C1=CC=CC=C1 OPIPFYKXYNLMGL-UHFFFAOYSA-N 0.000 description 4
- WGWNCAKNPSBPPM-UHFFFAOYSA-N 6-(1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C12=CC=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 WGWNCAKNPSBPPM-UHFFFAOYSA-N 0.000 description 4
- IZFZUQZBYVWIHC-UHFFFAOYSA-N 6-(1-methylpyrrol-2-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C=CC=C1C1=CC2=NC=CN=C2N1 IZFZUQZBYVWIHC-UHFFFAOYSA-N 0.000 description 4
- IKISMFQWQNPZGJ-UHFFFAOYSA-N 6-(1h-indol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C=3C4=CC=CC=C4NC=3)=CC2=N1 IKISMFQWQNPZGJ-UHFFFAOYSA-N 0.000 description 4
- TVMUETZKFBUXQB-UHFFFAOYSA-N 6-(3-methylindolizin-1-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC=CN2C(C)=CC(C=3NC4=NC=CN=C4C=3)=C21 TVMUETZKFBUXQB-UHFFFAOYSA-N 0.000 description 4
- XQYJBGKMIPFFJS-UHFFFAOYSA-N 6-(4-methoxyphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(OC)=CC=C1C1=CC2=NC=CN=C2N1 XQYJBGKMIPFFJS-UHFFFAOYSA-N 0.000 description 4
- OUDTUFDECCLCLN-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-7-methyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C)=C1C1=CC=C(C(C)(C)C)C=C1 OUDTUFDECCLCLN-UHFFFAOYSA-N 0.000 description 4
- BOAWWCKJPHLVFL-UHFFFAOYSA-N 6-(5-methoxy-1h-indol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=N1 BOAWWCKJPHLVFL-UHFFFAOYSA-N 0.000 description 4
- SLLSSLGVBCOGEU-UHFFFAOYSA-N 6-[3-(1,3-dioxan-2-yl)phenyl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound O1CCCOC1C1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 SLLSSLGVBCOGEU-UHFFFAOYSA-N 0.000 description 4
- KGGPSBLELUHYKI-UHFFFAOYSA-N 6-[4-(1,3-dioxan-2-yl)phenyl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound O1CCCOC1C1=CC=C(C=2NC3=NC=CN=C3C=2)C=C1 KGGPSBLELUHYKI-UHFFFAOYSA-N 0.000 description 4
- FCPZMXSDGNBSPP-UHFFFAOYSA-N 6-indolizin-1-yl-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C3=C4C=CC=CN4C=C3)=CC2=N1 FCPZMXSDGNBSPP-UHFFFAOYSA-N 0.000 description 4
- ONJMAXYFHBVNTH-UHFFFAOYSA-N 6-phenyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C=C1C1=CC=CC=C1 ONJMAXYFHBVNTH-UHFFFAOYSA-N 0.000 description 4
- 108091008875 B cell receptors Proteins 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- JARHJDCLSBJTAX-UHFFFAOYSA-N [1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxycyclobutyl]methanol Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(CO)CCC1 JARHJDCLSBJTAX-UHFFFAOYSA-N 0.000 description 4
- RKSSWPMEKJQARM-UHFFFAOYSA-N [3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]methanol Chemical compound C12=CC=CC=C2N(CO)C=C1C1=CC2=NC=CN=C2N1 RKSSWPMEKJQARM-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 125000003435 aroyl group Chemical group 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 150000004696 coordination complex Chemical class 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- SUVBMZUNTFWEAN-UHFFFAOYSA-N ethyl 2-[2-methoxy-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenoxy]acetate Chemical compound C1=C(OC)C(OCC(=O)OCC)=CC(C=2NC3=NC=CN=C3C=2)=C1 SUVBMZUNTFWEAN-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 4
- YORCGQINTQQCTH-UHFFFAOYSA-N n,1-dimethyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-amine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)NC)=CC2=C1 YORCGQINTQQCTH-UHFFFAOYSA-N 0.000 description 4
- OOVNCCJSGHIIQT-UHFFFAOYSA-N n,1-dimethyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NC)=CC2=N1 OOVNCCJSGHIIQT-UHFFFAOYSA-N 0.000 description 4
- DGTOUUXNYQOLBJ-UHFFFAOYSA-N n-(1,3-dihydroxypropan-2-yl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(CO)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 DGTOUUXNYQOLBJ-UHFFFAOYSA-N 0.000 description 4
- DBBLATGZGABQKN-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 DBBLATGZGABQKN-UHFFFAOYSA-N 0.000 description 4
- JOZNPCHRNZOWDU-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCO)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 JOZNPCHRNZOWDU-UHFFFAOYSA-N 0.000 description 4
- FXURAMRMAPFYLX-UHFFFAOYSA-N n-(2-methoxyethyl)pyridine-4-carboxamide Chemical compound COCCNC(=O)C1=CC=NC=C1 FXURAMRMAPFYLX-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- MUQFTYHVZUPXES-CYBMUJFWSA-N (2r)-3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropane-1,2-diol Chemical compound C12=CC(OC[C@H](O)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 MUQFTYHVZUPXES-CYBMUJFWSA-N 0.000 description 3
- SAYAZSFRHPSZLZ-CYBMUJFWSA-N (2r)-3-[6-methoxy-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropane-1,2-diol Chemical compound C1=CN=C2NC(C3=CN(C)C=4C=C(C(=CC=43)OC[C@H](O)CO)OC)=CC2=C1 SAYAZSFRHPSZLZ-CYBMUJFWSA-N 0.000 description 3
- NSNZZTVUYQKEMX-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1 NSNZZTVUYQKEMX-UHFFFAOYSA-N 0.000 description 3
- KGLJNKRRIRJQBS-UHFFFAOYSA-N 1-O-tert-butyl 5-O-methyl 3-bromoindole-1,5-dicarboxylate Chemical compound COC(=O)C=1C=C2C(=CN(C2=CC=1)C(=O)OC(C)(C)C)Br KGLJNKRRIRJQBS-UHFFFAOYSA-N 0.000 description 3
- ZUHZMIKTWRJJLA-UHFFFAOYSA-N 1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]ethanone Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)C)=CC2=C1 ZUHZMIKTWRJJLA-UHFFFAOYSA-N 0.000 description 3
- VGGBMWRHJWCWBG-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-n-(1h-1,2,4-triazol-5-yl)indole-6-carboxamide Chemical compound C1=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=C1C(=O)NC=1N=CNN=1 VGGBMWRHJWCWBG-UHFFFAOYSA-N 0.000 description 3
- NNASJUQMUFFFPP-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-amine Chemical compound C12=CC(N)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 NNASJUQMUFFFPP-UHFFFAOYSA-N 0.000 description 3
- AVNBDKGXTGVKOZ-UHFFFAOYSA-N 1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-ol Chemical compound C12=CC(O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 AVNBDKGXTGVKOZ-UHFFFAOYSA-N 0.000 description 3
- KJSSLGGIYSNMIX-UHFFFAOYSA-N 2-(1-methyl-4-phenylpyrrol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1N(C)C=C(C=2NC3=NC=CC=C3C=2)C=1C1=CC=CC=C1 KJSSLGGIYSNMIX-UHFFFAOYSA-N 0.000 description 3
- DFPXZCFFGKSGGH-UHFFFAOYSA-N 2-(1-methylpyrrol-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CN1C=CC=C1C1=CC2=CC=CN=C2N1 DFPXZCFFGKSGGH-UHFFFAOYSA-N 0.000 description 3
- XRBNURMPSOVRNI-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CNC(C=2NC3=NC=CC=C3C=2)=C1 XRBNURMPSOVRNI-UHFFFAOYSA-N 0.000 description 3
- WPAJCOUYLOSMJP-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-4-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC2=C(Cl)C=CN=C2N1 WPAJCOUYLOSMJP-UHFFFAOYSA-N 0.000 description 3
- IAFLZDODMZVUGY-UHFFFAOYSA-N 2-(5,6-dimethoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(C)C=3)OC)OC)=CC2=C1 IAFLZDODMZVUGY-UHFFFAOYSA-N 0.000 description 3
- YRIXXLQLBKMPFS-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-2-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C=3N(C)C4=CC=C(C=C4C=3)OC)=CC2=C1 YRIXXLQLBKMPFS-UHFFFAOYSA-N 0.000 description 3
- LPOOZQNTAHNETD-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-4-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2C1=CC=CC=C1 LPOOZQNTAHNETD-UHFFFAOYSA-N 0.000 description 3
- FKDHQBOTZUDZEJ-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-4-pyridin-3-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2C1=CC=CN=C1 FKDHQBOTZUDZEJ-UHFFFAOYSA-N 0.000 description 3
- IGGMDHNFNAGSFW-UHFFFAOYSA-N 2-(5h-pyrrolo[2,3-b]pyrazin-6-yl)quinoline Chemical compound C1=CC=CC2=NC(C3=CC4=NC=CN=C4N3)=CC=C21 IGGMDHNFNAGSFW-UHFFFAOYSA-N 0.000 description 3
- WHPGREASCBBEAV-UHFFFAOYSA-N 2-(6-phenyl-5h-pyrrolo[2,3-b]pyrazin-7-yl)ethanol Chemical compound N1C2=NC=CN=C2C(CCO)=C1C1=CC=CC=C1 WHPGREASCBBEAV-UHFFFAOYSA-N 0.000 description 3
- MCEGXLZIVNTQAG-UHFFFAOYSA-N 2-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxyacetic acid Chemical compound C12=CC(OCC(O)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 MCEGXLZIVNTQAG-UHFFFAOYSA-N 0.000 description 3
- NGRLVNLOYHSCOT-UHFFFAOYSA-N 2-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxyethanol Chemical compound C12=CC(OCCO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 NGRLVNLOYHSCOT-UHFFFAOYSA-N 0.000 description 3
- COKIRTGHADVGEP-UHFFFAOYSA-N 2-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropan-1-ol Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC(CO)C)=CC2=C1 COKIRTGHADVGEP-UHFFFAOYSA-N 0.000 description 3
- FPFNTCBEXLWOSS-UHFFFAOYSA-N 2-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropanoic acid Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC(C)C(O)=O)=CC2=C1 FPFNTCBEXLWOSS-UHFFFAOYSA-N 0.000 description 3
- MCTZIYPXXHBZEW-UHFFFAOYSA-N 2-[1-methyl-5-(2-methyltetrazol-5-yl)indol-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CN1N=NC(C=2C=C3C(C=4NC5=NC=CC=C5C=4)=CN(C)C3=CC=2)=N1 MCTZIYPXXHBZEW-UHFFFAOYSA-N 0.000 description 3
- DJRQUOXUSPPFSR-UHFFFAOYSA-N 2-[2-methoxy-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(OC)=CC=C1C1=CC2=NC=CN=C2N1 DJRQUOXUSPPFSR-UHFFFAOYSA-N 0.000 description 3
- KMNMIJBFIPKXKD-UHFFFAOYSA-N 2-[2-methoxy-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenoxy]ethanol Chemical compound C1=C(OCCO)C(OC)=CC=C1C1=CC2=NC=CN=C2N1 KMNMIJBFIPKXKD-UHFFFAOYSA-N 0.000 description 3
- JPDDXTCUOWHSQE-UHFFFAOYSA-N 2-[5,6-dimethoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C=2NC3=NC=CC=C3C=2)=CN1CC(=O)N1CCOCC1 JPDDXTCUOWHSQE-UHFFFAOYSA-N 0.000 description 3
- NVNRNJUWUKDPHD-UHFFFAOYSA-N 2-[5,6-dimethoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetic acid Chemical compound C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(CC(O)=O)C=3)OC)OC)=CC2=C1 NVNRNJUWUKDPHD-UHFFFAOYSA-N 0.000 description 3
- BJBMPYZXKSTFJM-UHFFFAOYSA-N 2-[5-(1-methoxypropan-2-yloxy)-1-methylindol-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC(C)COC)=CC2=C1 BJBMPYZXKSTFJM-UHFFFAOYSA-N 0.000 description 3
- KQPOMDOVRNSQIS-UHFFFAOYSA-N 2-[5-methoxy-1-(2-morpholin-4-yl-2-oxoethyl)indol-3-yl]-1h-pyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C1=C(C=2NC3=NC=CC(=C3C=2)C#N)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 KQPOMDOVRNSQIS-UHFFFAOYSA-N 0.000 description 3
- SMCLLQQYFYBQQL-UHFFFAOYSA-N 2-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]ethanol Chemical compound C1=CN=C2NC(C3=CN(CCO)C4=CC=C(C=C43)OC)=CC2=N1 SMCLLQQYFYBQQL-UHFFFAOYSA-N 0.000 description 3
- XLDRLTCJIPGWKZ-UHFFFAOYSA-N 2-methoxy-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenol Chemical compound C1=C(O)C(OC)=CC=C1C1=CC2=NC=CN=C2N1 XLDRLTCJIPGWKZ-UHFFFAOYSA-N 0.000 description 3
- SSYNYIMWLZUVAP-UHFFFAOYSA-N 3,5-dimethyl-4-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]-1,2-oxazole Chemical compound CC1=NOC(C)=C1C1=CC=C(C=2NC3=NC=CN=C3C=2)C=C1 SSYNYIMWLZUVAP-UHFFFAOYSA-N 0.000 description 3
- JHUWLGXCOIMHHQ-UHFFFAOYSA-N 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indole-5-carboxylic acid Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)C(=O)O)=CC2=C1 JHUWLGXCOIMHHQ-UHFFFAOYSA-N 0.000 description 3
- HIWPOKJDACYAFJ-UHFFFAOYSA-N 3-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-2-yl)-1-methylindole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2C(C=3NC=4N=CC=C(C=4C=3)OC)=CN(C)C2=C1 HIWPOKJDACYAFJ-UHFFFAOYSA-N 0.000 description 3
- ZHIVJCAOHXULET-UHFFFAOYSA-N 3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)benzaldehyde Chemical compound O=CC1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 ZHIVJCAOHXULET-UHFFFAOYSA-N 0.000 description 3
- WEUYJMOQLNSRHF-UHFFFAOYSA-N 3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)isoquinoline Chemical compound C1=CC=C2C=NC(C3=CC4=NC=CN=C4N3)=CC2=C1 WEUYJMOQLNSRHF-UHFFFAOYSA-N 0.000 description 3
- KERGNDFCTBAMGA-UHFFFAOYSA-N 3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropan-1-ol Chemical compound C12=CC(OCCCO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 KERGNDFCTBAMGA-UHFFFAOYSA-N 0.000 description 3
- MUQFTYHVZUPXES-UHFFFAOYSA-N 3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropane-1,2-diol Chemical compound C12=CC(OCC(O)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 MUQFTYHVZUPXES-UHFFFAOYSA-N 0.000 description 3
- BZGCYSXNPHENAB-UHFFFAOYSA-N 3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]propanoic acid Chemical compound C12=CC(CCC(O)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 BZGCYSXNPHENAB-UHFFFAOYSA-N 0.000 description 3
- HJVIRZPDKZDCRL-UHFFFAOYSA-N 3-[2-(dimethylamino)-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-1-ol Chemical compound C1=C(CCCO)C(N(C)C)=CC=C1C1=CC2=NC=CN=C2N1 HJVIRZPDKZDCRL-UHFFFAOYSA-N 0.000 description 3
- JLUFLHFTAWTMKE-UHFFFAOYSA-N 3-[2-(dimethylamino)-5-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propanoic acid Chemical compound C1=C(CCC(O)=O)C(N(C)C)=CC=C1C1=CC2=NC=CN=C2N1 JLUFLHFTAWTMKE-UHFFFAOYSA-N 0.000 description 3
- NCQLLGRVUVRYAL-UHFFFAOYSA-N 3-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propan-1-amine Chemical compound C12=CC=CC=C2N(CCCN)C=C1C1=CC2=NC=CN=C2N1 NCQLLGRVUVRYAL-UHFFFAOYSA-N 0.000 description 3
- AUWZEPCLXNUNJU-UHFFFAOYSA-N 3-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propan-1-amine Chemical compound C1=CN=C2NC(C3=CN(CCCN)C4=CC=C(C=C43)OC)=CC2=N1 AUWZEPCLXNUNJU-UHFFFAOYSA-N 0.000 description 3
- LEKQOMRWKOCLNB-UHFFFAOYSA-N 3-[6-(4-fluorophenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-n-methylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C1=CC=C(F)C=C1 LEKQOMRWKOCLNB-UHFFFAOYSA-N 0.000 description 3
- YXOCECKDUCUKPX-UHFFFAOYSA-N 3-[6-(4-fluorophenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanoic acid Chemical compound N1C2=NC=CN=C2C(CCC(=O)O)=C1C1=CC=C(F)C=C1 YXOCECKDUCUKPX-UHFFFAOYSA-N 0.000 description 3
- OAPAMBQQVWOUSF-UHFFFAOYSA-N 3-[6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-N-methylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C1=CC=C(O)C=C1 OAPAMBQQVWOUSF-UHFFFAOYSA-N 0.000 description 3
- ZZICCIIULWMGFF-UHFFFAOYSA-N 3-[6-(4-methoxyphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-n-methylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C1=CC=C(OC)C=C1 ZZICCIIULWMGFF-UHFFFAOYSA-N 0.000 description 3
- FEAXJWJFDJCIMM-UHFFFAOYSA-N 3-[6-(4-methoxyphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanoic acid Chemical compound C1=CC(OC)=CC=C1C1=C(CCC(O)=O)C2=NC=CN=C2N1 FEAXJWJFDJCIMM-UHFFFAOYSA-N 0.000 description 3
- VYADGIBPWMJLTF-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propan-1-ol Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCCO)C2=NC=CN=C2N1 VYADGIBPWMJLTF-UHFFFAOYSA-N 0.000 description 3
- PYDLJXBLJBPZNI-UHFFFAOYSA-N 3-methyl-6-(1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC=C2C(C3=CC4=NC=C(N=C4N3)C)=CN(C)C2=C1 PYDLJXBLJBPZNI-UHFFFAOYSA-N 0.000 description 3
- JZGBONHLJLFZPT-UHFFFAOYSA-N 4-(5H-pyrrolo[2,3-b]pyrazin-6-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=CC2=NC=CN=C2N1 JZGBONHLJLFZPT-UHFFFAOYSA-N 0.000 description 3
- RJCNFODBLALXCM-UHFFFAOYSA-N 4-(7-methyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)aniline Chemical compound N1C2=NC=CN=C2C(C)=C1C1=CC=C(N)C=C1 RJCNFODBLALXCM-UHFFFAOYSA-N 0.000 description 3
- HEVJMLZQASVXPM-UHFFFAOYSA-N 4-[2-[5,6-dimethoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethyl]morpholine Chemical compound C1=2C=C(OC)C(OC)=CC=2C(C=2NC3=NC=CC=C3C=2)=CN1CCN1CCOCC1 HEVJMLZQASVXPM-UHFFFAOYSA-N 0.000 description 3
- YKEWIZLNUZNKTF-UHFFFAOYSA-N 4-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-2-methylbutan-2-ol Chemical compound N1C2=NC=CN=C2C(CCC(C)(O)C)=C1C1=CC=C(C(C)(C)C)C=C1 YKEWIZLNUZNKTF-UHFFFAOYSA-N 0.000 description 3
- HNTZVGMWXCFCTA-UHFFFAOYSA-N 4-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=NC2=C1C=CN2 HNTZVGMWXCFCTA-UHFFFAOYSA-N 0.000 description 3
- LMHHYPOKWRDJTP-UHFFFAOYSA-N 4-chloro-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1Cl LMHHYPOKWRDJTP-UHFFFAOYSA-N 0.000 description 3
- BJUASEJFANEFJD-UHFFFAOYSA-N 4-chloro-2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=C(Cl)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 BJUASEJFANEFJD-UHFFFAOYSA-N 0.000 description 3
- OOZQRJFRYLCREJ-UHFFFAOYSA-N 4-chloro-2-iodo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(Cl)=C2C=C1I OOZQRJFRYLCREJ-UHFFFAOYSA-N 0.000 description 3
- JFFMPLDYSOUBPW-UHFFFAOYSA-N 4-methoxy-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1OC JFFMPLDYSOUBPW-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- IIZURLNRIMKEDL-UHFFFAOYSA-N 4-tert-butylbenzonitrile Chemical compound CC(C)(C)C1=CC=C(C#N)C=C1 IIZURLNRIMKEDL-UHFFFAOYSA-N 0.000 description 3
- CZFFYXFWPCJEGW-UHFFFAOYSA-N 5-methoxy-1h-indole-3-carbonitrile Chemical compound COC1=CC=C2NC=C(C#N)C2=C1 CZFFYXFWPCJEGW-UHFFFAOYSA-N 0.000 description 3
- NMMCYAVAWKMNJH-UHFFFAOYSA-N 5-methyl-3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]-1,2,4-oxadiazole Chemical compound O1C(C)=NC(C=2C=C3C(C=4NC5=NC=CC=C5C=4)=CN(C)C3=CC=2)=N1 NMMCYAVAWKMNJH-UHFFFAOYSA-N 0.000 description 3
- REGLPYFBVKECSK-UHFFFAOYSA-N 6-(1,4-dimethylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CC1=CN(C)C=C1C1=CC2=NC=CN=C2N1 REGLPYFBVKECSK-UHFFFAOYSA-N 0.000 description 3
- INOGZQRUJJRLMW-UHFFFAOYSA-N 6-(1,5-dimethylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C(C)=CC(C=2NC3=NC=CN=C3C=2)=C1 INOGZQRUJJRLMW-UHFFFAOYSA-N 0.000 description 3
- PKNKYWXKDIEEGA-UHFFFAOYSA-N 6-(1-methyl-2-phenylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C=CC(C=2NC3=NC=CN=C3C=2)=C1C1=CC=CC=C1 PKNKYWXKDIEEGA-UHFFFAOYSA-N 0.000 description 3
- UJGWDQOREZNCCC-UHFFFAOYSA-N 6-(1-methyl-5-phenylpyrazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine Chemical compound CN1N=C(C=2NC3=NC=CN=C3C=2)C=C1C1=CC=CC=C1 UJGWDQOREZNCCC-UHFFFAOYSA-N 0.000 description 3
- QYJOXPGTOAYSBH-UHFFFAOYSA-N 6-(1-methyl-5-phenylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C=C(C=2NC3=NC=CN=C3C=2)C=C1C1=CC=CC=C1 QYJOXPGTOAYSBH-UHFFFAOYSA-N 0.000 description 3
- NSROKWNOZRNWPF-UHFFFAOYSA-N 6-(1-methylindazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine Chemical compound C12=CC=CC=C2N(C)N=C1C1=CC2=NC=CN=C2N1 NSROKWNOZRNWPF-UHFFFAOYSA-N 0.000 description 3
- BYAZDVQHMGZBBN-UHFFFAOYSA-N 6-(1-methylpyrazol-4-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=NN(C)C=C1C1=CC2=NC=CN=C2N1 BYAZDVQHMGZBBN-UHFFFAOYSA-N 0.000 description 3
- QUDOYZVSZNJAJI-UHFFFAOYSA-N 6-(1-methylpyrrol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CN1C=CC(C=2NC3=NC=CN=C3C=2)=C1 QUDOYZVSZNJAJI-UHFFFAOYSA-N 0.000 description 3
- NFCCSXCXRYCSRB-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC2=NC=CN=C2N1 NFCCSXCXRYCSRB-UHFFFAOYSA-N 0.000 description 3
- OCDUBFIMRNXMGM-UHFFFAOYSA-N 6-(3-bromophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound BrC1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 OCDUBFIMRNXMGM-UHFFFAOYSA-N 0.000 description 3
- MFDLPDIVXMMWSI-UHFFFAOYSA-N 6-(3-methoxyphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound COC1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 MFDLPDIVXMMWSI-UHFFFAOYSA-N 0.000 description 3
- ZIPGRNBNZKOCNS-UHFFFAOYSA-N 6-(4-bromophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(Br)=CC=C1C1=CC2=NC=CN=C2N1 ZIPGRNBNZKOCNS-UHFFFAOYSA-N 0.000 description 3
- OGRORAFGBNLUSP-UHFFFAOYSA-N 6-(4-fluorophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(F)=CC=C1C1=CC2=NC=CN=C2N1 OGRORAFGBNLUSP-UHFFFAOYSA-N 0.000 description 3
- NUKABDWWQOLSDM-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC2=NC=CN=C2N1 NUKABDWWQOLSDM-UHFFFAOYSA-N 0.000 description 3
- YEYZRVNDUWRTNQ-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-7-prop-1-enyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C=CC)=C1C1=CC=C(C(C)(C)C)C=C1 YEYZRVNDUWRTNQ-UHFFFAOYSA-N 0.000 description 3
- RQFHBMHSUJNCTI-UHFFFAOYSA-N 6-(5,6,7,8-tetrahydroindolizin-1-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C=3C=CN4CCCCC4=3)=CC2=N1 RQFHBMHSUJNCTI-UHFFFAOYSA-N 0.000 description 3
- SILSHTRJCCPNFE-UHFFFAOYSA-N 6-(furan-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound O1C=CC(C=2NC3=NC=CN=C3C=2)=C1 SILSHTRJCCPNFE-UHFFFAOYSA-N 0.000 description 3
- GIJWLMVJORUCKS-UHFFFAOYSA-N 6-methoxy-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-ol Chemical compound C1=CN=C2NC(C3=CN(C)C=4C=C(C(=CC=43)O)OC)=CC2=C1 GIJWLMVJORUCKS-UHFFFAOYSA-N 0.000 description 3
- IXQOVNQMUSNLCC-UHFFFAOYSA-N 6-pyridin-2-yl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C=C1C1=CC=CC=N1 IXQOVNQMUSNLCC-UHFFFAOYSA-N 0.000 description 3
- HRMXBNUSPZDBGZ-UHFFFAOYSA-N 6-pyridin-4-yl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C=C1C1=CC=NC=C1 HRMXBNUSPZDBGZ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102100035634 B-cell linker protein Human genes 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108010016672 Syk Kinase Proteins 0.000 description 3
- 235000004338 Syringa vulgaris Nutrition 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- XIHWGXJGOTZLIG-UHFFFAOYSA-N [1-[5-[1-(hydroxymethyl)cyclobutyl]oxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]cyclobutyl]methanol Chemical compound C=1C=C2N(C3(CO)CCC3)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(CO)CCC1 XIHWGXJGOTZLIG-UHFFFAOYSA-N 0.000 description 3
- YYOYJSYGHIOCEG-UHFFFAOYSA-N [1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-5-yl]-morpholin-4-ylmethanone Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CN=C4C=3)C2=CC=1C(=O)N1CCOCC1 YYOYJSYGHIOCEG-UHFFFAOYSA-N 0.000 description 3
- OEDIEPSQOFBRLC-UHFFFAOYSA-N [2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]-morpholin-4-ylmethanone Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2C(=O)N1CCOCC1 OEDIEPSQOFBRLC-UHFFFAOYSA-N 0.000 description 3
- DHKLVRHQKKFFDV-UHFFFAOYSA-N [4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl] trifluoromethanesulfonate Chemical compound C1=CC(OS(=O)(=O)C(F)(F)F)=CC=C1C1=CC2=NC=CN=C2N1 DHKLVRHQKKFFDV-UHFFFAOYSA-N 0.000 description 3
- SAAPTVBNHZPVGQ-UHFFFAOYSA-N [4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]methanol Chemical compound C1=CC(CO)=CC=C1C1=CC2=NC=CN=C2N1 SAAPTVBNHZPVGQ-UHFFFAOYSA-N 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 3
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
- 125000005110 aryl thio group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- RSDOASZYYCOXIB-UHFFFAOYSA-N beta-alaninamide Chemical compound NCCC(N)=O RSDOASZYYCOXIB-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000010504 bond cleavage reaction Methods 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- PIKSZCHZASBHEM-UHFFFAOYSA-N ethyl 3-[[1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carbonyl]amino]propanoate Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NCCC(=O)OCC)=CC2=N1 PIKSZCHZASBHEM-UHFFFAOYSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 3
- 125000005553 heteroaryloxy group Chemical group 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000006192 iodination reaction Methods 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- DRYBMFJLYYEOBZ-UHFFFAOYSA-N methyl 1h-indole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NC=CC2=C1 DRYBMFJLYYEOBZ-UHFFFAOYSA-N 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- SAXZZQKRYZIXGK-UHFFFAOYSA-N n,1-dimethyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NC)=CC2=C1 SAXZZQKRYZIXGK-UHFFFAOYSA-N 0.000 description 3
- GQZGUPUPTQVLPU-UHFFFAOYSA-N n-(1,3-dihydroxypropan-2-yl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-6-carboxamide Chemical compound C12=CC=C(C(=O)NC(CO)CO)C=C2N(C)C=C1C1=CC2=CC=CN=C2N1 GQZGUPUPTQVLPU-UHFFFAOYSA-N 0.000 description 3
- IARCJGCMPYDUMM-UHFFFAOYSA-N n-(2-fluoroethyl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCF)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 IARCJGCMPYDUMM-UHFFFAOYSA-N 0.000 description 3
- XZRYCTLOGNCQDG-UHFFFAOYSA-N n-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(C)(C)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 XZRYCTLOGNCQDG-UHFFFAOYSA-N 0.000 description 3
- FOMSGDOUGOTANG-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-6-carboxamide Chemical compound C12=CC=C(C(=O)NCCO)C=C2N(C)C=C1C1=CC2=CC=CN=C2N1 FOMSGDOUGOTANG-UHFFFAOYSA-N 0.000 description 3
- QVPWDPDVDVVXIB-UHFFFAOYSA-N n-(2-hydroxyethyl)pyridine-4-carboxamide Chemical compound OCCNC(=O)C1=CC=NC=C1 QVPWDPDVDVVXIB-UHFFFAOYSA-N 0.000 description 3
- AQXRBEHWQCOKJI-UHFFFAOYSA-N n-(2-hydroxypropyl)pyridine-4-carboxamide Chemical compound CC(O)CNC(=O)C1=CC=NC=C1 AQXRBEHWQCOKJI-UHFFFAOYSA-N 0.000 description 3
- CJEABCXNJXZHHG-UHFFFAOYSA-N n-(2-methoxyethyl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NCCOC)=CC2=N1 CJEABCXNJXZHHG-UHFFFAOYSA-N 0.000 description 3
- PWQQTIQWOQXEMI-UHFFFAOYSA-N n-(3-amino-3-oxopropyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCC(N)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 PWQQTIQWOQXEMI-UHFFFAOYSA-N 0.000 description 3
- FYCVBBKHRJDKDP-UHFFFAOYSA-N n-(3-amino-3-oxopropyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-6-carboxamide Chemical compound C12=CC=C(C(=O)NCCC(N)=O)C=C2N(C)C=C1C1=CC2=CC=CN=C2N1 FYCVBBKHRJDKDP-UHFFFAOYSA-N 0.000 description 3
- IFEWOIRZUBHZIP-UHFFFAOYSA-N n-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)NC(=O)C)=CC2=C1 IFEWOIRZUBHZIP-UHFFFAOYSA-N 0.000 description 3
- SQDCWXJFPMNDRX-UHFFFAOYSA-N n-[3-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propyl]acetamide Chemical compound C12=CC=CC=C2N(CCCNC(=O)C)C=C1C1=CC2=NC=CN=C2N1 SQDCWXJFPMNDRX-UHFFFAOYSA-N 0.000 description 3
- QKFJBWBEBJDNBL-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]acetamide Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)C)=C1C1=CC=C(C(C)(C)C)C=C1 QKFJBWBEBJDNBL-UHFFFAOYSA-N 0.000 description 3
- ZWAXAAAYMBSOIA-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]methanesulfonamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCCNS(C)(=O)=O)C2=NC=CN=C2N1 ZWAXAAAYMBSOIA-UHFFFAOYSA-N 0.000 description 3
- VVPZZIYCYCXVGG-UHFFFAOYSA-N n-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CC2=NC=CN=C2N1 VVPZZIYCYCXVGG-UHFFFAOYSA-N 0.000 description 3
- VROZAWKQBHASNN-UHFFFAOYSA-N n-methyl-1-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxycyclobutane-1-carboxamide Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1OC1(C(=O)NC)CCC1 VROZAWKQBHASNN-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003791 organic solvent mixture Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- AVMLLCMOHIXKQU-UHFFFAOYSA-M potassium;2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxylate Chemical compound [K+].C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1C([O-])=O AVMLLCMOHIXKQU-UHFFFAOYSA-M 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940080818 propionamide Drugs 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- JKVRTUCVPZTEQZ-UHFFFAOYSA-N tributyltin azide Chemical compound CCCC[Sn](CCCC)(CCCC)N=[N+]=[N-] JKVRTUCVPZTEQZ-UHFFFAOYSA-N 0.000 description 3
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 3
- FZRRMJVEUXGESA-UHFFFAOYSA-N trimethyl-[2-[[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]methoxy]ethyl]silane Chemical compound C12=CC=CC=C2N(COCC[Si](C)(C)C)C=C1C1=CC2=NC=CN=C2N1 FZRRMJVEUXGESA-UHFFFAOYSA-N 0.000 description 3
- MUQFTYHVZUPXES-ZDUSSCGKSA-N (2s)-3-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]oxypropane-1,2-diol Chemical compound C12=CC(OC[C@@H](O)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 MUQFTYHVZUPXES-ZDUSSCGKSA-N 0.000 description 2
- DIIFZCPZIRQDIJ-UHFFFAOYSA-N (3,5-dimethyl-1,2-oxazol-4-yl)boronic acid Chemical compound CC1=NOC(C)=C1B(O)O DIIFZCPZIRQDIJ-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- ZCPVXUJWWDIBHV-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-2-(1h-pyrrol-2-yl)pyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CC=CN1 ZCPVXUJWWDIBHV-UHFFFAOYSA-N 0.000 description 2
- CQMNXGKPHXDEBC-UHFFFAOYSA-N 1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-5-methoxyindole-3-carbonitrile Chemical compound COC1=CC=C2N(CCO[Si](C)(C)C(C)(C)C)C=C(C#N)C2=C1 CQMNXGKPHXDEBC-UHFFFAOYSA-N 0.000 description 2
- PZTSFYSEWYAIQG-UHFFFAOYSA-N 1-[2-[tert-butyl(dimethyl)silyl]oxyethyl]indole-3-carbonitrile Chemical compound C1=CC=C2N(CCO[Si](C)(C)C(C)(C)C)C=C(C#N)C2=C1 PZTSFYSEWYAIQG-UHFFFAOYSA-N 0.000 description 2
- CYSYOXMYZXJMHB-UHFFFAOYSA-N 1-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]-3-propylurea Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)NCCC)=C1C1=CC=C(C(C)(C)C)C=C1 CYSYOXMYZXJMHB-UHFFFAOYSA-N 0.000 description 2
- SPDIACBHWWVGJH-UHFFFAOYSA-N 1-[3-[tert-butyl(dimethyl)silyl]oxypropyl]-5-methoxyindole-3-carbonitrile Chemical compound COC1=CC=C2N(CCCO[Si](C)(C)C(C)(C)C)C=C(C#N)C2=C1 SPDIACBHWWVGJH-UHFFFAOYSA-N 0.000 description 2
- SLRXMXLZWJBYRT-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCC1(O)C1=CC=C(Cl)C=C1 SLRXMXLZWJBYRT-UHFFFAOYSA-N 0.000 description 2
- ZLMRGHXNFAWRDV-UHFFFAOYSA-N 1-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC2=NC=CN=C2N1 ZLMRGHXNFAWRDV-UHFFFAOYSA-N 0.000 description 2
- AHRLDZHURASTFL-UHFFFAOYSA-N 1-benzyl-5-methoxyindole-3-carbonitrile Chemical compound C1=C(C#N)C2=CC(OC)=CC=C2N1CC1=CC=CC=C1 AHRLDZHURASTFL-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- SZQNDWMUYSGRHG-UHFFFAOYSA-N 1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)-n-(2-thiophen-2-ylethyl)indole-5-carboxamide Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CN=C4C=3)C2=CC=1C(=O)NCCC1=CC=CS1 SZQNDWMUYSGRHG-UHFFFAOYSA-N 0.000 description 2
- SDDGDIPSSYMLOY-UHFFFAOYSA-N 1-methyl-4-phenylpyrrole-3-carbonitrile Chemical compound CN1C=C(C#N)C(C=2C=CC=CC=2)=C1 SDDGDIPSSYMLOY-UHFFFAOYSA-N 0.000 description 2
- AGEKFZHCMVDIFA-UHFFFAOYSA-N 1-methyl-5-phenylpyrazole-3-carbaldehyde Chemical compound CN1N=C(C=O)C=C1C1=CC=CC=C1 AGEKFZHCMVDIFA-UHFFFAOYSA-N 0.000 description 2
- AMDSSWGEPMPSIT-UHFFFAOYSA-N 1-methyl-5-phenylpyrrole-3-carbonitrile Chemical compound CN1C=C(C#N)C=C1C1=CC=CC=C1 AMDSSWGEPMPSIT-UHFFFAOYSA-N 0.000 description 2
- LHAADVRTPWTUSV-UHFFFAOYSA-N 1-methyl-n-(2-morpholin-4-ylethyl)-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1C(=O)NCCN1CCOCC1 LHAADVRTPWTUSV-UHFFFAOYSA-N 0.000 description 2
- KGWGSWFHKGVCLZ-UHFFFAOYSA-N 1-methyl-n-[3-(methylamino)-3-oxopropyl]-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)NCCC(=O)NC)=CC2=N1 KGWGSWFHKGVCLZ-UHFFFAOYSA-N 0.000 description 2
- DYZZFEHAJOLDEX-UHFFFAOYSA-N 1-methylindole-5-carbonitrile Chemical compound N#CC1=CC=C2N(C)C=CC2=C1 DYZZFEHAJOLDEX-UHFFFAOYSA-N 0.000 description 2
- JRQSGIQEBOZPHK-UHFFFAOYSA-N 1-methylpyrrole-2-carbonitrile Chemical compound CN1C=CC=C1C#N JRQSGIQEBOZPHK-UHFFFAOYSA-N 0.000 description 2
- VZSLEHOZJCZYJD-UHFFFAOYSA-N 1-methylpyrrole-3-carbonitrile Chemical compound CN1C=CC(C#N)=C1 VZSLEHOZJCZYJD-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- YHYLDEVWYOFIJK-UHFFFAOYSA-N 1h-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NC=CC2=C1 YHYLDEVWYOFIJK-UHFFFAOYSA-N 0.000 description 2
- BQMPGKPTOHKYHS-UHFFFAOYSA-N 1h-pyrrole-2-carbonitrile Chemical compound N#CC1=CC=CN1 BQMPGKPTOHKYHS-UHFFFAOYSA-N 0.000 description 2
- LCZUOKDVTBMCMX-UHFFFAOYSA-N 2,5-Dimethylpyrazine Chemical compound CC1=CN=C(C)C=N1 LCZUOKDVTBMCMX-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 239000001934 2,5-dimethylpyrazine Substances 0.000 description 2
- HJFZAYHYIWGLNL-UHFFFAOYSA-N 2,6-Dimethylpyrazine Chemical compound CC1=CN=CC(C)=N1 HJFZAYHYIWGLNL-UHFFFAOYSA-N 0.000 description 2
- KELLLGDNFSNCIO-UHFFFAOYSA-N 2-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)acetonitrile Chemical compound N1C2=NC=CC=C2C(CC#N)=C1C1=CC=CC=C1 KELLLGDNFSNCIO-UHFFFAOYSA-N 0.000 description 2
- YIRMQTLNXUASMD-UHFFFAOYSA-N 2-(5,6-dimethoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 YIRMQTLNXUASMD-UHFFFAOYSA-N 0.000 description 2
- JQEYBGCZTGRKPH-UHFFFAOYSA-N 2-(5-methoxy-1-methyl-6-propan-2-yloxyindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(C)C=3)OC(C)C)OC)=CC2=C1 JQEYBGCZTGRKPH-UHFFFAOYSA-N 0.000 description 2
- ZVEJOVUCQDIHIC-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-3-methyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CN(C)C2=CC=C(OC)C=C21 ZVEJOVUCQDIHIC-UHFFFAOYSA-N 0.000 description 2
- RCDWHRTWJKHQPB-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-5-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=2)=CC1=CC=2C1=CC=CC=C1 RCDWHRTWJKHQPB-UHFFFAOYSA-N 0.000 description 2
- LUPHPGSKPAIRRH-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonyl-4-phenylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=C(C=3C=CC=CC=3)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 LUPHPGSKPAIRRH-UHFFFAOYSA-N 0.000 description 2
- HAVHMUAYDBZNOM-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonyl-5-phenylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=CC(C=3C=CC=CC=3)=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 HAVHMUAYDBZNOM-UHFFFAOYSA-N 0.000 description 2
- JGUMBSXAPVHWIQ-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 JGUMBSXAPVHWIQ-UHFFFAOYSA-N 0.000 description 2
- KGQLZBXQDDLVNZ-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1C(N)=O KGQLZBXQDDLVNZ-UHFFFAOYSA-N 0.000 description 2
- MLKNJZRTQBQQHR-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-3-methyl-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2NC=C1C1=C(C)C2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 MLKNJZRTQBQQHR-UHFFFAOYSA-N 0.000 description 2
- PZAZYCCMMOILTO-UHFFFAOYSA-N 2-(5-methoxy-6-phenylmethoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound COC1=CC=2C(C=3N(C4=NC=CC=C4C=3)S(=O)(=O)C=3C=CC(C)=CC=3)=CNC=2C=C1OCC1=CC=CC=C1 PZAZYCCMMOILTO-UHFFFAOYSA-N 0.000 description 2
- RNEMGTWKDYOKCY-UHFFFAOYSA-N 2-(6-methoxy-5-phenylmethoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=2C=C(OCC=3C=CC=CC=3)C(OC)=CC=2NC=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 RNEMGTWKDYOKCY-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- BBHXAEXXTCXRHL-UHFFFAOYSA-N 2-[1-methyl-5-(1-methyltetrazol-5-yl)indol-3-yl]-1h-pyrrolo[2,3-b]pyridine Chemical compound CN1N=NN=C1C1=CC=C(N(C)C=C2C=3NC4=NC=CC=C4C=3)C2=C1 BBHXAEXXTCXRHL-UHFFFAOYSA-N 0.000 description 2
- TZZCKBOVBQPDIU-UHFFFAOYSA-N 2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=CC=C1C1=CC2=CC=CN=C2N1 TZZCKBOVBQPDIU-UHFFFAOYSA-N 0.000 description 2
- VFIDFFAQOVMDBB-UHFFFAOYSA-N 2-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]ethanol Chemical compound C12=CC=CC=C2N(CCO)C=C1C1=CC2=NC=CN=C2N1 VFIDFFAQOVMDBB-UHFFFAOYSA-N 0.000 description 2
- GOMJCRVLUHYUCB-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 GOMJCRVLUHYUCB-UHFFFAOYSA-N 0.000 description 2
- AKSKFTWNVYJOKH-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-methylquinolin-4-yl)acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C5=CC=CC=C5N=C(C)C=4)C4=CC=C(C=C43)OC)=CC2=C1 AKSKFTWNVYJOKH-UHFFFAOYSA-N 0.000 description 2
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 2
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 2
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 2
- UKVQBONVSSLJBB-UHFFFAOYSA-N 2-pyridin-2-ylacetonitrile Chemical compound N#CCC1=CC=CC=N1 UKVQBONVSSLJBB-UHFFFAOYSA-N 0.000 description 2
- HVLUYXIJZLDNIS-UHFFFAOYSA-N 2-thiophen-2-ylethanamine Chemical compound NCCC1=CC=CS1 HVLUYXIJZLDNIS-UHFFFAOYSA-N 0.000 description 2
- OWISXYQFTOYGRO-UHFFFAOYSA-N 3,4-dimethylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1C OWISXYQFTOYGRO-UHFFFAOYSA-N 0.000 description 2
- KYPQVDBNGSPUDJ-UHFFFAOYSA-N 3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]-1h-indole-5-carbonitrile Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CNC2=CC=C(C#N)C=C12 KYPQVDBNGSPUDJ-UHFFFAOYSA-N 0.000 description 2
- MMWCUAAXINWETB-UHFFFAOYSA-N 3-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]-1,1-diethylurea Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)N(CC)CC)=C1C1=CC=C(C(C)(C)C)C=C1 MMWCUAAXINWETB-UHFFFAOYSA-N 0.000 description 2
- QUWWKACRKZQBDN-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-ylpropan-1-one Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)N1CCOCC1 QUWWKACRKZQBDN-UHFFFAOYSA-N 0.000 description 2
- DVUJAEITDIFDJD-UHFFFAOYSA-N 3-bromo-6-methoxy-5-phenylmethoxyindole-1-carboxylic acid Chemical compound COC1=CC=2N(C(O)=O)C=C(Br)C=2C=C1OCC1=CC=CC=C1 DVUJAEITDIFDJD-UHFFFAOYSA-N 0.000 description 2
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 2
- MTTCOBLSWWQVDL-UHFFFAOYSA-N 3-fluoro-2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(F)=C1C1=CN(C)C2=CC=C(OC)C=C21 MTTCOBLSWWQVDL-UHFFFAOYSA-N 0.000 description 2
- YCQRBNHIBAGRDM-UHFFFAOYSA-N 3-methylindolizine-1-carbonitrile Chemical compound C1=CC=CN2C(C)=CC(C#N)=C21 YCQRBNHIBAGRDM-UHFFFAOYSA-N 0.000 description 2
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- OZRZOPXIQIDGSR-UHFFFAOYSA-N 4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC2=NC=CN=C2N1 OZRZOPXIQIDGSR-UHFFFAOYSA-N 0.000 description 2
- QNNURFLOTYFVLC-UHFFFAOYSA-N 4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)benzaldehyde;hydrate Chemical compound O.C1=CC(C=O)=CC=C1C1=CC2=NC=CN=C2N1 QNNURFLOTYFVLC-UHFFFAOYSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- FKJHUONFOWJTPO-UHFFFAOYSA-N 4-[2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-4-yl]-3,5-dimethyl-1,2-oxazole Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=C(C3=C(ON=C3C)C)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 FKJHUONFOWJTPO-UHFFFAOYSA-N 0.000 description 2
- XMFLIOYKQXKSHH-UHFFFAOYSA-N 4-[2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridin-4-yl]morpholine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C(NC1=NC=C2)=CC1=C2N1CCOCC1 XMFLIOYKQXKSHH-UHFFFAOYSA-N 0.000 description 2
- LXOIWJAQWBJLLV-UHFFFAOYSA-N 4-[2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-4-yl]-3,5-dimethyl-1,2-oxazole Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=C(C3=C(ON=C3C)C)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 LXOIWJAQWBJLLV-UHFFFAOYSA-N 0.000 description 2
- HLUPMPDGNNAHRZ-UHFFFAOYSA-N 4-[2-[4-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]piperazin-1-yl]ethyl]morpholine Chemical compound C1CN(C=2C=CC(=CC=2)C=2NC3=NC=CN=C3C=2)CCN1CCN1CCOCC1 HLUPMPDGNNAHRZ-UHFFFAOYSA-N 0.000 description 2
- YQCGVJONPZWTKO-UHFFFAOYSA-N 4-[2-iodo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-4-yl]-3,5-dimethyl-1,2-oxazole Chemical compound CC1=NOC(C)=C1C1=CC=NC2=C1C=C(I)N2S(=O)(=O)C1=CC=C(C)C=C1 YQCGVJONPZWTKO-UHFFFAOYSA-N 0.000 description 2
- XPDBSYYQEBBVHZ-UHFFFAOYSA-N 4-[3-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propyl]morpholine Chemical compound C1=C(C=2NC3=NC=CN=C3C=2)C2=CC=CC=C2N1CCCN1CCOCC1 XPDBSYYQEBBVHZ-UHFFFAOYSA-N 0.000 description 2
- QCYZWVVKBMGGBM-UHFFFAOYSA-N 4-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]butan-2-one Chemical compound N1C2=NC=CN=C2C(CCC(=O)C)=C1C1=CC=C(C(C)(C)C)C=C1 QCYZWVVKBMGGBM-UHFFFAOYSA-N 0.000 description 2
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 2
- HYHQFHGGYUZYKX-UHFFFAOYSA-N 4-chloro-2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=C(Cl)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 HYHQFHGGYUZYKX-UHFFFAOYSA-N 0.000 description 2
- TYXWDMWSFQYDKQ-UHFFFAOYSA-N 4-diphenylphosphanylbutan-2-yl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)C(C)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 TYXWDMWSFQYDKQ-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- PPRZWBLCPANUPB-UHFFFAOYSA-N 4-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=2C(C)=CC=NC=2NC=1C1=CC=CC=C1 PPRZWBLCPANUPB-UHFFFAOYSA-N 0.000 description 2
- HEXWGHMYABJLGV-UHFFFAOYSA-N 5-methoxy-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-6-ol Chemical compound C1=CN=C2NC(C=3C=4C=C(C(=CC=4N(C)C=3)O)OC)=CC2=C1 HEXWGHMYABJLGV-UHFFFAOYSA-N 0.000 description 2
- HFTVJMFWJUFBNO-UHFFFAOYSA-N 5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC=CC2=N1 HFTVJMFWJUFBNO-UHFFFAOYSA-N 0.000 description 2
- ZVYIHCXPWGXHDU-UHFFFAOYSA-N 6-(1-methylindol-5-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C=3C=C4C=CN(C4=CC=3)C)=CC2=N1 ZVYIHCXPWGXHDU-UHFFFAOYSA-N 0.000 description 2
- WPZBQHHKIFAYMT-UHFFFAOYSA-N 6-(2-chloro-5-methoxy-1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC(C3=C(Cl)N(C)C4=CC=C(C=C43)OC)=CC2=N1 WPZBQHHKIFAYMT-UHFFFAOYSA-N 0.000 description 2
- VOYATMLQGSEKER-UHFFFAOYSA-N 6-(3,4-dimethylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(C)C(C)=CC=C1C1=CC2=NC=CN=C2N1 VOYATMLQGSEKER-UHFFFAOYSA-N 0.000 description 2
- ZNIORXXXAJEYQH-UHFFFAOYSA-N 6-(4-methylsulfinylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(S(=O)C)=CC=C1C1=CC2=NC=CN=C2N1 ZNIORXXXAJEYQH-UHFFFAOYSA-N 0.000 description 2
- VPRBEBVRGIGTGF-UHFFFAOYSA-N 6-(4-methylsulfonylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC2=NC=CN=C2N1 VPRBEBVRGIGTGF-UHFFFAOYSA-N 0.000 description 2
- IQFCDWGPPITEID-UHFFFAOYSA-N 6-(4-pyrrolidin-1-ylphenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1CCCN1C1=CC=C(C=2NC3=NC=CN=C3C=2)C=C1 IQFCDWGPPITEID-UHFFFAOYSA-N 0.000 description 2
- WCMRADNCDSUPBD-UHFFFAOYSA-N 6-(5-methoxy-1-methylindol-3-yl)-2-methyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound CC1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=N1 WCMRADNCDSUPBD-UHFFFAOYSA-N 0.000 description 2
- FFKTVFFDFAAUHY-UHFFFAOYSA-N 6-(5-methoxy-1-methylindol-3-yl)-7-methyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C)=C1C1=CN(C)C2=CC=C(OC)C=C21 FFKTVFFDFAAUHY-UHFFFAOYSA-N 0.000 description 2
- GXYKGJZXOCFTBB-UHFFFAOYSA-N 6-[1-(3-bromopropyl)indol-3-yl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C12=CC=CC=C2N(CCCBr)C=C1C1=CC2=NC=CN=C2N1 GXYKGJZXOCFTBB-UHFFFAOYSA-N 0.000 description 2
- ISQUBBNHUIOYBD-UHFFFAOYSA-N 6-[1-(3-piperidin-1-ylpropyl)indol-3-yl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(C=2NC3=NC=CN=C3C=2)C2=CC=CC=C2N1CCCN1CCCCC1 ISQUBBNHUIOYBD-UHFFFAOYSA-N 0.000 description 2
- RNHXCQLEULNFPV-UHFFFAOYSA-N 6-[1-(3-pyridin-3-yloxypropyl)indol-3-yl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=C(C=2NC3=NC=CN=C3C=2)C2=CC=CC=C2N1CCCOC1=CC=CN=C1 RNHXCQLEULNFPV-UHFFFAOYSA-N 0.000 description 2
- KHKWNJPABRVFFN-UHFFFAOYSA-N 6-[4-(furan-2-yl)phenyl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=COC(C=2C=CC(=CC=2)C=2NC3=NC=CN=C3C=2)=C1 KHKWNJPABRVFFN-UHFFFAOYSA-N 0.000 description 2
- NDHSCNJZSAUAEW-UHFFFAOYSA-N 6-[4-(trifluoromethoxy)phenyl]-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=CC2=NC=CN=C2N1 NDHSCNJZSAUAEW-UHFFFAOYSA-N 0.000 description 2
- LVARNOHOOZOAGQ-UHFFFAOYSA-N 6-phenyl-7-propan-2-yl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C(C)C)=C1C1=CC=CC=C1 LVARNOHOOZOAGQ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 101710083670 B-cell linker protein Proteins 0.000 description 2
- WOZQIGMZRYCWDG-UHFFFAOYSA-N C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)N(CCO)C(=O)OC)=CC2=N1 Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)N(CCO)C(=O)OC)=CC2=N1 WOZQIGMZRYCWDG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 241000400611 Eucalyptus deanei Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000000551 Syk Kinase Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- CWEMKTADLXMJOP-UHFFFAOYSA-N [3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]methanol Chemical compound OCC1=CC=CC(C=2NC3=NC=CN=C3C=2)=C1 CWEMKTADLXMJOP-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- WRYNUJYAXVDTCB-UHFFFAOYSA-M acetyloxymercury Chemical compound CC(=O)O[Hg] WRYNUJYAXVDTCB-UHFFFAOYSA-M 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000005239 aroylamino group Chemical group 0.000 description 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- OGODKNYCTJYXFF-UHFFFAOYSA-N bis(4-methylbenzoyl) 2,3-dihydroxybutanedioate Chemical compound C1=CC(C)=CC=C1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=C(C)C=C1 OGODKNYCTJYXFF-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000024321 chromosome segregation Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- UFKWQVIEIUDCJR-UHFFFAOYSA-N ethyl 2-[1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-yl]oxypropanoate Chemical compound C12=CC(OC(C)C(=O)OCC)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 UFKWQVIEIUDCJR-UHFFFAOYSA-N 0.000 description 2
- GDMNEKQQFQMIMP-UHFFFAOYSA-N ethyl 2-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propylcarbamoylamino]acetate Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)NCC(=O)OCC)=C1C1=CC=C(C(C)(C)C)C=C1 GDMNEKQQFQMIMP-UHFFFAOYSA-N 0.000 description 2
- KUMRTJNGPLSWHP-UHFFFAOYSA-N ethyl 3-[6-(4-hydroxyphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]propanoate Chemical compound N1C2=NC=CN=C2C(CCC(=O)OCC)=C1C1=CC=C(O)C=C1 KUMRTJNGPLSWHP-UHFFFAOYSA-N 0.000 description 2
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 2
- SMVBADCAMQOTOV-UHFFFAOYSA-N ethyl cyclobutanecarboxylate Chemical compound CCOC(=O)C1CCC1 SMVBADCAMQOTOV-UHFFFAOYSA-N 0.000 description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- IKMSBSJONUMYEI-UHFFFAOYSA-N indolizine-1-carbonitrile Chemical compound C1=CC=CC2=C(C#N)C=CN21 IKMSBSJONUMYEI-UHFFFAOYSA-N 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- SEGAYCRVQDVTNC-UHFFFAOYSA-N methanesulfonic acid;6-(5-methoxy-1-methylindol-3-yl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound CS(O)(=O)=O.C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=N1 SEGAYCRVQDVTNC-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BCIQPEJQGWEOKV-UHFFFAOYSA-N methyl 1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indole-5-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 BCIQPEJQGWEOKV-UHFFFAOYSA-N 0.000 description 2
- PNHYXWFKLVHIRS-UHFFFAOYSA-N methyl 3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]-1h-indole-6-carboxylate Chemical compound C=1NC2=CC(C(=O)OC)=CC=C2C=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 PNHYXWFKLVHIRS-UHFFFAOYSA-N 0.000 description 2
- QVMJZZJJCNERMM-UHFFFAOYSA-N methyl 3-[4-chloro-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]-1H-indole-5-carboxylate Chemical compound COC(=O)C=1C=C2C(=CNC2=CC1)C1=CC=2C(=NC=CC2Cl)N1S(=O)(=O)C1=CC=C(C)C=C1 QVMJZZJJCNERMM-UHFFFAOYSA-N 0.000 description 2
- YBKNLXRDWFAEPO-UHFFFAOYSA-N methyl 3-[4-methoxy-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]-1H-indole-5-carboxylate Chemical compound COC(=O)C=1C=C2C(=CNC2=CC1)C1=CC=2C(=NC=CC2OC)N1S(=O)(=O)C1=CC=C(C)C=C1 YBKNLXRDWFAEPO-UHFFFAOYSA-N 0.000 description 2
- CAWHJQAVHZEVTJ-UHFFFAOYSA-N methylpyrazine Chemical compound CC1=CN=CC=N1 CAWHJQAVHZEVTJ-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- OOWFNUNLQJGMIX-UHFFFAOYSA-N n,n,1-trimethyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)N(C)C)=CC2=N1 OOWFNUNLQJGMIX-UHFFFAOYSA-N 0.000 description 2
- OHHAGYLFBKMMNS-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)N(CCO)CCO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 OHHAGYLFBKMMNS-UHFFFAOYSA-N 0.000 description 2
- MCWHFEZTUZXKFF-UHFFFAOYSA-N n,n-dimethyl-4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)aniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC2=NC=CN=C2N1 MCWHFEZTUZXKFF-UHFFFAOYSA-N 0.000 description 2
- JRPKEYZLZFIJOB-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)-1h-indole-5-carboxamide Chemical compound OCC(C)(C)NC(=O)C1=CC=C2NC=CC2=C1 JRPKEYZLZFIJOB-UHFFFAOYSA-N 0.000 description 2
- OEXSEKPUBPFSBH-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCC(O)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 OEXSEKPUBPFSBH-UHFFFAOYSA-N 0.000 description 2
- VGCUIRGNMBJIJN-UHFFFAOYSA-N n-(3-hydroxypropyl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NCCCO)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 VGCUIRGNMBJIJN-UHFFFAOYSA-N 0.000 description 2
- DXDHILMEBJRQBQ-UHFFFAOYSA-N n-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(CO)(CO)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 DXDHILMEBJRQBQ-UHFFFAOYSA-N 0.000 description 2
- LMQAALQEYGOOIO-UHFFFAOYSA-N n-[1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-5-yl]methanesulfonamide Chemical compound C12=CC(NS(C)(=O)=O)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 LMQAALQEYGOOIO-UHFFFAOYSA-N 0.000 description 2
- DCVMKOMYZCLPRK-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]-2-methoxyacetamide Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)COC)=C1C1=CC=C(C(C)(C)C)C=C1 DCVMKOMYZCLPRK-UHFFFAOYSA-N 0.000 description 2
- VFFVWJYTTADYPM-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]butanamide Chemical compound N1C2=NC=CN=C2C(CCCNC(=O)CCC)=C1C1=CC=C(C(C)(C)C)C=C1 VFFVWJYTTADYPM-UHFFFAOYSA-N 0.000 description 2
- JGMAAZXDUNJODZ-UHFFFAOYSA-N n-[3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propyl]cyclopropanecarboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCCNC(=O)C2CC2)C2=NC=CN=C2N1 JGMAAZXDUNJODZ-UHFFFAOYSA-N 0.000 description 2
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 2
- LWNOUSJECJEDNF-UHFFFAOYSA-N n-methyl-3-[6-(4-morpholin-4-ylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C(C=C1)=CC=C1N1CCOCC1 LWNOUSJECJEDNF-UHFFFAOYSA-N 0.000 description 2
- PLWAKFARFCNHJO-UHFFFAOYSA-N n-methylpyridine-4-carboxamide Chemical compound CNC(=O)C1=CC=NC=C1 PLWAKFARFCNHJO-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000003909 protein kinase inhibitor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- GTIVKALLFZZJFA-UHFFFAOYSA-N tert-butyl-[2-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]ethoxy]-dimethylsilane Chemical compound C1=CN=C2NC(C3=CN(CCO[Si](C)(C)C(C)(C)C)C4=CC=C(C=C43)OC)=CC2=N1 GTIVKALLFZZJFA-UHFFFAOYSA-N 0.000 description 2
- RZMPCCIQPRHXCC-UHFFFAOYSA-N tert-butyl-[3-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propoxy]-dimethylsilane Chemical compound C1=CN=C2NC(C3=CN(CCCO[Si](C)(C)C(C)(C)C)C4=CC=C(C=C43)OC)=CC2=N1 RZMPCCIQPRHXCC-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- VNNLHYZDXIBHKZ-UHFFFAOYSA-N thiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CS1 VNNLHYZDXIBHKZ-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- LGQXXHMEBUOXRP-UHFFFAOYSA-N tributyl borate Chemical compound CCCCOB(OCCCC)OCCCC LGQXXHMEBUOXRP-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical class O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- MNJYZNVROSZZQC-UHFFFAOYSA-N (4-tert-butylphenyl)boronic acid Chemical compound CC(C)(C)C1=CC=C(B(O)O)C=C1 MNJYZNVROSZZQC-UHFFFAOYSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- ABFQGXBZQWZNKI-UHFFFAOYSA-N 1,1-dimethoxyethanol Chemical compound COC(C)(O)OC ABFQGXBZQWZNKI-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 150000000183 1,3-benzoxazoles Chemical class 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- JCQGMSHWWIIMLE-UHFFFAOYSA-N 1,4-dimethylpyrrole-3-carbonitrile Chemical compound CC1=CN(C)C=C1C#N JCQGMSHWWIIMLE-UHFFFAOYSA-N 0.000 description 1
- SMEUSSLSLVISEV-UHFFFAOYSA-N 1,5-dimethylpyrrole-3-carbonitrile Chemical compound CC1=CC(C#N)=CN1C SMEUSSLSLVISEV-UHFFFAOYSA-N 0.000 description 1
- KZJLTGRDWWXYHJ-UHFFFAOYSA-N 1-(2,5-dihydropyrrol-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CC=CC1 KZJLTGRDWWXYHJ-UHFFFAOYSA-N 0.000 description 1
- UCPREHUNIGUZHI-UHFFFAOYSA-N 1-(2,6-dimethylmorpholin-4-yl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1C(C)OC(C)CN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 UCPREHUNIGUZHI-UHFFFAOYSA-N 0.000 description 1
- LVTUIWBHHMEGKI-UHFFFAOYSA-N 1-(2,6-dimethylmorpholin-4-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CC(C)OC(C)C1 LVTUIWBHHMEGKI-UHFFFAOYSA-N 0.000 description 1
- GFBOETCIFYIFSB-UHFFFAOYSA-N 1-(2-trimethylsilylethoxymethyl)indole-3-carbonitrile Chemical compound C1=CC=C2N(COCC[Si](C)(C)C)C=C(C#N)C2=C1 GFBOETCIFYIFSB-UHFFFAOYSA-N 0.000 description 1
- KHDZWUJSJVMBHB-UHFFFAOYSA-N 1-(3,3-dimethylpiperidin-1-yl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1C(C)(C)CCCN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 KHDZWUJSJVMBHB-UHFFFAOYSA-N 0.000 description 1
- OCESAMICSQEKCC-UHFFFAOYSA-N 1-(3,3-dimethylpiperidin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCCC(C)(C)C1 OCESAMICSQEKCC-UHFFFAOYSA-N 0.000 description 1
- DDWNQFWAEZKZHO-UHFFFAOYSA-N 1-(3,6-dihydro-2h-pyridin-1-yl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1CC(=O)N1CCC=CC1 DDWNQFWAEZKZHO-UHFFFAOYSA-N 0.000 description 1
- XHVDYZJWVTWBCD-UHFFFAOYSA-N 1-(3,6-dihydro-2h-pyridin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCC=CC1 XHVDYZJWVTWBCD-UHFFFAOYSA-N 0.000 description 1
- HXVXATGYSIUQDR-UHFFFAOYSA-N 1-(4-benzhydrylpiperazin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 HXVXATGYSIUQDR-UHFFFAOYSA-N 0.000 description 1
- WXYLXNBCVLDZAR-UHFFFAOYSA-N 1-(4-benzylpiperazin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1CC1=CC=CC=C1 WXYLXNBCVLDZAR-UHFFFAOYSA-N 0.000 description 1
- LXIYPROGDBDNIS-UHFFFAOYSA-N 1-(4-hydroxypiperidin-1-yl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1CC(O)CCN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 LXIYPROGDBDNIS-UHFFFAOYSA-N 0.000 description 1
- QUFQKOIFRJLLKN-UHFFFAOYSA-N 1-(4-hydroxypiperidin-1-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCC(O)CC1 QUFQKOIFRJLLKN-UHFFFAOYSA-N 0.000 description 1
- OONRFRRMUYCEEB-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-2-(1-methyl-5-pyridin-4-ylindol-3-yl)pyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CN(C)C2=CC=C(C=3C=CN=CC=3)C=C12 OONRFRRMUYCEEB-UHFFFAOYSA-N 0.000 description 1
- WZVHBNGMCBANPQ-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-2-(1-methylpyrrol-2-yl)pyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CC=CN1C WZVHBNGMCBANPQ-UHFFFAOYSA-N 0.000 description 1
- STUDQQYVWIKSEJ-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-4-pyridin-3-ylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(C=3C=NC=CC=3)=C2C=C1 STUDQQYVWIKSEJ-UHFFFAOYSA-N 0.000 description 1
- XXANCZBGOITVHB-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonylindole-5-carboxylic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=CC=C(C(O)=O)C=C2C=C1 XXANCZBGOITVHB-UHFFFAOYSA-N 0.000 description 1
- PXZVUUSOHKXROL-UHFFFAOYSA-N 1-(4-methylpiperazin-1-yl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1CN(C)CCN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 PXZVUUSOHKXROL-UHFFFAOYSA-N 0.000 description 1
- NFGXAVBYYOUVQS-UHFFFAOYSA-N 1-[3-[tert-butyl(dimethyl)silyl]oxypropyl]indole-3-carbonitrile Chemical compound C1=CC=C2N(CCCO[Si](C)(C)C(C)(C)C)C=C(C#N)C2=C1 NFGXAVBYYOUVQS-UHFFFAOYSA-N 0.000 description 1
- AHPXVOLHKQCJCR-UHFFFAOYSA-N 1-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=CN=C2NC(C3=CN(CC(=O)N4CCN(CC=5C=C6OCOC6=CC=5)CC4)C4=CC=C(C=C43)OC)=CC2=C1 AHPXVOLHKQCJCR-UHFFFAOYSA-N 0.000 description 1
- VRGGJGJITGEMAJ-UHFFFAOYSA-N 1-[4-(3-hydroxyphenyl)piperazin-1-yl]-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound OC1=CC=CC(N2CCN(CC2)C(=O)CN2C(=CC=C2)C=2NC3=NC=CC=C3C=2)=C1 VRGGJGJITGEMAJ-UHFFFAOYSA-N 0.000 description 1
- STJRMIZUUDFYEG-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCC1(O)C1=CC=C(Cl)C=C1 STJRMIZUUDFYEG-UHFFFAOYSA-N 0.000 description 1
- RHYQATNAXYUWJU-UHFFFAOYSA-N 1-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1CC1=CC=C(Cl)C=C1 RHYQATNAXYUWJU-UHFFFAOYSA-N 0.000 description 1
- MRBZEZBWAHYDSR-UHFFFAOYSA-N 1-[4-[(4-tert-butylphenyl)methyl]piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1CC1=CC=C(C(C)(C)C)C=C1 MRBZEZBWAHYDSR-UHFFFAOYSA-N 0.000 description 1
- NMFMLXBMWOFCHQ-UHFFFAOYSA-N 1-[4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCN(CCOCCO)CC1 NMFMLXBMWOFCHQ-UHFFFAOYSA-N 0.000 description 1
- KSIZKFJYVIZTDJ-UHFFFAOYSA-N 1-[4-[2-(dimethylamino)ethyl]piperazin-1-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCN(CCN(C)C)CC1 KSIZKFJYVIZTDJ-UHFFFAOYSA-N 0.000 description 1
- BAIMGIJCZXNMGZ-UHFFFAOYSA-N 1-[4-[3-(dimethylamino)propyl]piperazin-1-yl]-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1CN(CCCN(C)C)CCN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 BAIMGIJCZXNMGZ-UHFFFAOYSA-N 0.000 description 1
- OQURWGJAWSLGQG-UHFFFAOYSA-N 1-isocyanatopropane Chemical compound CCCN=C=O OQURWGJAWSLGQG-UHFFFAOYSA-N 0.000 description 1
- SIZVCQPCIHCEFE-UHFFFAOYSA-N 1-methyl-2-phenylpyrrole-3-carbonitrile Chemical compound CN1C=CC(C#N)=C1C1=CC=CC=C1 SIZVCQPCIHCEFE-UHFFFAOYSA-N 0.000 description 1
- ORAALBRTYXFNGK-UHFFFAOYSA-N 1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-ol Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CN(C)C2=CC=C(O)C=C12 ORAALBRTYXFNGK-UHFFFAOYSA-N 0.000 description 1
- DFHPOROHGLPIEI-UHFFFAOYSA-N 1-methyl-4-[2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetyl]piperazin-2-one Chemical compound C1C(=O)N(C)CCN1C(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 DFHPOROHGLPIEI-UHFFFAOYSA-N 0.000 description 1
- CTVJCXXBSZEUHR-UHFFFAOYSA-N 1-methyl-5-phenylpyrazole-3-carbonitrile Chemical compound CN1N=C(C#N)C=C1C1=CC=CC=C1 CTVJCXXBSZEUHR-UHFFFAOYSA-N 0.000 description 1
- KXUGUWTUFUWYRS-UHFFFAOYSA-N 1-methylimidazole-4-sulfonyl chloride Chemical compound CN1C=NC(S(Cl)(=O)=O)=C1 KXUGUWTUFUWYRS-UHFFFAOYSA-N 0.000 description 1
- XXPCFXLOLXYNRI-UHFFFAOYSA-N 1-methylindazole-3-carbonitrile Chemical compound C1=CC=C2N(C)N=C(C#N)C2=C1 XXPCFXLOLXYNRI-UHFFFAOYSA-N 0.000 description 1
- NIBQNKBEGIMBSV-UHFFFAOYSA-N 1-methylpyrazole-4-carbonitrile Chemical compound CN1C=C(C#N)C=N1 NIBQNKBEGIMBSV-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- QGSWCWANVQUOBH-UHFFFAOYSA-N 1-o-tert-butyl 6-o-methyl 3-bromoindole-1,6-dicarboxylate Chemical compound COC(=O)C1=CC=C2C(Br)=CN(C(=O)OC(C)(C)C)C2=C1 QGSWCWANVQUOBH-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- PDQUKYDVXKBRAF-UHFFFAOYSA-N 1-pyrrolidin-1-yl-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]ethanone Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1CC(=O)N1CCCC1 PDQUKYDVXKBRAF-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- ZCBIFHNDZBSCEP-UHFFFAOYSA-N 1H-indol-5-amine Chemical compound NC1=CC=C2NC=CC2=C1 ZCBIFHNDZBSCEP-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- PCYWMDGJYQAMCR-UHFFFAOYSA-N 1h-pyrrole-3-carbonitrile Chemical compound N#CC=1C=CNC=1 PCYWMDGJYQAMCR-UHFFFAOYSA-N 0.000 description 1
- HVPYZVWMSSBUNJ-UHFFFAOYSA-N 2-(1-ethyl-5-methoxyindol-3-yl)-n-(1-hydroxy-2-methylpropan-2-yl)-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C12=CC(OC)=CC=C2N(CC)C=C1C1=CC2=C(C(=O)NC(C)(C)CO)C=CN=C2N1 HVPYZVWMSSBUNJ-UHFFFAOYSA-N 0.000 description 1
- RYWGGRZTKNVSPR-UHFFFAOYSA-N 2-(1-methyl-5-pyridin-4-ylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=C2N(C)C=C(C=3NC4=NC=CC=C4C=3)C2=CC=1C1=CC=NC=C1 RYWGGRZTKNVSPR-UHFFFAOYSA-N 0.000 description 1
- KLGCAAPGEFYSET-UHFFFAOYSA-N 2-(1H-indole-5-carbonylamino)propanoic acid Chemical compound OC(=O)C(C)NC(=O)C1=CC=C2NC=CC2=C1 KLGCAAPGEFYSET-UHFFFAOYSA-N 0.000 description 1
- YAIMUUJMEBJXAA-UHFFFAOYSA-N 2-(2-methylpropyl)pyrazine Chemical compound CC(C)CC1=CN=CC=N1 YAIMUUJMEBJXAA-UHFFFAOYSA-N 0.000 description 1
- IURSYUWVAYZMLX-UHFFFAOYSA-N 2-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)acetamide Chemical compound N1C2=NC=CC=C2C(CC(=O)N)=C1C1=CC=CC=C1 IURSYUWVAYZMLX-UHFFFAOYSA-N 0.000 description 1
- QOWCSDWRCIPYJJ-UHFFFAOYSA-N 2-(4-bromophenyl)-3-methyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CC=C(Br)C=C1 QOWCSDWRCIPYJJ-UHFFFAOYSA-N 0.000 description 1
- PAUWEYGKUDICMQ-UHFFFAOYSA-N 2-(4-chlorophenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(Cl)=CC=C1C1=CC2=CC=CN=C2N1 PAUWEYGKUDICMQ-UHFFFAOYSA-N 0.000 description 1
- SHISXEDJQZVJAL-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(OC)=CC=C1C1=CC2=CC=CN=C2N1 SHISXEDJQZVJAL-UHFFFAOYSA-N 0.000 description 1
- UNQRREMUTOUZSE-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-methyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(OC)=CC=C1C1=C(C)C2=CC=CN=C2N1 UNQRREMUTOUZSE-UHFFFAOYSA-N 0.000 description 1
- JRGNVEQMRMUETH-UHFFFAOYSA-N 2-(4-tert-butylphenyl)-4-chloro-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(Cl)=C2C=C1C1=CC=C(C(C)(C)C)C=C1 JRGNVEQMRMUETH-UHFFFAOYSA-N 0.000 description 1
- ZKXQECJYTFRWGA-UHFFFAOYSA-N 2-(5,6-dimethoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C=1N(C)C=2C=C(OC)C(OC)=CC=2C=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 ZKXQECJYTFRWGA-UHFFFAOYSA-N 0.000 description 1
- JZSAWHOFIOPYNV-UHFFFAOYSA-N 2-(5-methoxy-1-methyl-6-propan-2-yloxyindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C=1N(C)C=2C=C(OC(C)C)C(OC)=CC=2C=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 JZSAWHOFIOPYNV-UHFFFAOYSA-N 0.000 description 1
- FOZXYWPWVMFMHY-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-2-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C=1C2=CC(OC)=CC=C2N(C)C=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 FOZXYWPWVMFMHY-UHFFFAOYSA-N 0.000 description 1
- PMPACJBHNPDHAR-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonyl-4-phenylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=C(C=3C=CC=CC=3)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 PMPACJBHNPDHAR-UHFFFAOYSA-N 0.000 description 1
- MRZAFOHXWPRVPQ-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 MRZAFOHXWPRVPQ-UHFFFAOYSA-N 0.000 description 1
- RBSGVNMWVSAEOL-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=C(C#N)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 RBSGVNMWVSAEOL-UHFFFAOYSA-N 0.000 description 1
- CBFKLVAQWIOSOV-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)-3-methyl-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=C(C)C2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 CBFKLVAQWIOSOV-UHFFFAOYSA-N 0.000 description 1
- NCDPLYGICALYGV-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-2-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C=1C2=CC(OC)=CC=C2NC=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 NCDPLYGICALYGV-UHFFFAOYSA-N 0.000 description 1
- HIAIAXLVQQWPNW-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-1-(4-methylphenyl)sulfonyl-4-pyridin-3-ylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2NC=C1C1=CC2=C(C=3C=NC=CC=3)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 HIAIAXLVQQWPNW-UHFFFAOYSA-N 0.000 description 1
- IGRYIGZITBPHMV-UHFFFAOYSA-N 2-(5-methoxy-1h-indol-3-yl)-n-methyl-1h-pyrrolo[2,3-b]pyridine-4-carboxamide Chemical compound C1=C(OC)C=C2C(C=3NC=4N=CC=C(C=4C=3)C(=O)NC)=CNC2=C1 IGRYIGZITBPHMV-UHFFFAOYSA-N 0.000 description 1
- NTXNTJKCZGSAKO-UHFFFAOYSA-N 2-(6-phenyl-5h-pyrrolo[2,3-b]pyrazin-7-yl)acetic acid Chemical compound N1C2=NC=CN=C2C(CC(=O)O)=C1C1=CC=CC=C1 NTXNTJKCZGSAKO-UHFFFAOYSA-N 0.000 description 1
- RZQPWQDWYMDQHQ-UHFFFAOYSA-N 2-(bromomethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCBr RZQPWQDWYMDQHQ-UHFFFAOYSA-N 0.000 description 1
- KPUOXMBOZWPIBK-UHFFFAOYSA-N 2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]-1-thiomorpholin-4-ylethanone Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1CC(=O)N1CCSCC1 KPUOXMBOZWPIBK-UHFFFAOYSA-N 0.000 description 1
- BPJQLQMFOWMKNO-UHFFFAOYSA-N 2-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol Chemical compound C1=CC(C(C)(O)C)=CC=C1C1=CC2=NC=CN=C2N1 BPJQLQMFOWMKNO-UHFFFAOYSA-N 0.000 description 1
- LMMQGYQWBOBVSP-UHFFFAOYSA-N 2-[5,6-dimethoxy-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-1-yl]acetic acid Chemical compound C=1N(CC(O)=O)C=2C=C(OC)C(OC)=CC=2C=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 LMMQGYQWBOBVSP-UHFFFAOYSA-N 0.000 description 1
- JFOZGRYEVSDSGW-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(1,3-thiazolidin-3-yl)ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCSC1 JFOZGRYEVSDSGW-UHFFFAOYSA-N 0.000 description 1
- OEJANAGBQNONLV-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(3-methylpiperazin-1-yl)ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCNC(C)C1 OEJANAGBQNONLV-UHFFFAOYSA-N 0.000 description 1
- BXPYGBUPFAJHEM-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1CCN1CCOCC1 BXPYGBUPFAJHEM-UHFFFAOYSA-N 0.000 description 1
- DYOUPYMZDDHSEF-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-[4-(3-methylphenyl)piperazin-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1C1=CC=CC(C)=C1 DYOUPYMZDDHSEF-UHFFFAOYSA-N 0.000 description 1
- ACZHQUXATMMPLP-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-[4-(oxolane-2-carbonyl)piperazin-1-yl]ethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CC1)CCN1C(=O)C1CCCO1 ACZHQUXATMMPLP-UHFFFAOYSA-N 0.000 description 1
- XMXDQCRUWXHMBD-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-piperidin-1-ylethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCCCC1 XMXDQCRUWXHMBD-UHFFFAOYSA-N 0.000 description 1
- NELKYKMFCBJEKH-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-pyrrolidin-1-ylethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCCC1 NELKYKMFCBJEKH-UHFFFAOYSA-N 0.000 description 1
- PNQZHGQOQVJUFV-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-thiomorpholin-4-ylethanone Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCSCC1 PNQZHGQOQVJUFV-UHFFFAOYSA-N 0.000 description 1
- OVMCATWJGAKILF-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-methylcyclohexyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CCCCC1C OVMCATWJGAKILF-UHFFFAOYSA-N 0.000 description 1
- WFKQXJDWKOBQKM-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-methylpropyl)acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NCC(C)C)C4=CC=C(C=C43)OC)=CC2=C1 WFKQXJDWKOBQKM-UHFFFAOYSA-N 0.000 description 1
- DYJCPBAQGVSXMD-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-phenylsulfanylethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCSC1=CC=CC=C1 DYJCPBAQGVSXMD-UHFFFAOYSA-N 0.000 description 1
- ZJRMHCBWQNCDCN-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-piperidin-1-ylethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCN1CCCCC1 ZJRMHCBWQNCDCN-UHFFFAOYSA-N 0.000 description 1
- XBGORNDCEPLSDY-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-pyridin-4-ylethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCC1=CC=NC=C1 XBGORNDCEPLSDY-UHFFFAOYSA-N 0.000 description 1
- HMDOBUOYJXHSQG-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(2-pyrrolidin-1-ylethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCN1CCCC1 HMDOBUOYJXHSQG-UHFFFAOYSA-N 0.000 description 1
- GAQSDLALUSQSCO-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(3-methylbutan-2-yl)acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC(C)C(C)C)C4=CC=C(C=C43)OC)=CC2=C1 GAQSDLALUSQSCO-UHFFFAOYSA-N 0.000 description 1
- UDCRMLPEZMWHKH-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(3-methylbutyl)acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NCCC(C)C)C4=CC=C(C=C43)OC)=CC2=C1 UDCRMLPEZMWHKH-UHFFFAOYSA-N 0.000 description 1
- IFOXNFQUBVQIBF-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(3-oxo-1,2-oxazolidin-4-yl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CONC1=O IFOXNFQUBVQIBF-UHFFFAOYSA-N 0.000 description 1
- SBRQMBKXTAWGCK-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(3-phenylmethoxypyridin-2-yl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1=NC=CC=C1OCC1=CC=CC=C1 SBRQMBKXTAWGCK-UHFFFAOYSA-N 0.000 description 1
- RUQQVNMGWNCECS-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(3-pyrrolidin-1-ylpropyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCCN1CCCC1 RUQQVNMGWNCECS-UHFFFAOYSA-N 0.000 description 1
- BGIPIZFHVWJSCZ-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(4-morpholin-4-ylphenyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(C=C1)=CC=C1N1CCOCC1 BGIPIZFHVWJSCZ-UHFFFAOYSA-N 0.000 description 1
- RODKSYLFQRPFDT-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(4-phenylbutan-2-yl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(C)CCC1=CC=CC=C1 RODKSYLFQRPFDT-UHFFFAOYSA-N 0.000 description 1
- KUTAWJWZJYRUQB-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(oxolan-2-ylmethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCC1CCCO1 KUTAWJWZJYRUQB-UHFFFAOYSA-N 0.000 description 1
- NCYPGKCZJOISEV-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(pyridin-2-ylmethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCC1=CC=CC=N1 NCYPGKCZJOISEV-UHFFFAOYSA-N 0.000 description 1
- LOFRLFDLBCLBOZ-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-[3-(2-oxopyrrolidin-1-yl)propyl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCCN1CCCC1=O LOFRLFDLBCLBOZ-UHFFFAOYSA-N 0.000 description 1
- FKVQFHKOOGPTLG-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-[3-(4-methylpiperazin-1-yl)propyl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCCN1CCN(C)CC1 FKVQFHKOOGPTLG-UHFFFAOYSA-N 0.000 description 1
- SUOVCTWFKJKPPB-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-methyl-n-(pyridin-3-ylmethyl)acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(C)CC1=CC=CN=C1 SUOVCTWFKJKPPB-UHFFFAOYSA-N 0.000 description 1
- LYNAZMGLZOUVDV-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-quinolin-2-ylacetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4N=C5C=CC=CC5=CC=4)C4=CC=C(C=C43)OC)=CC2=C1 LYNAZMGLZOUVDV-UHFFFAOYSA-N 0.000 description 1
- XVYFBCKOJVBDOF-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-quinolin-3-ylacetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C=C5C=CC=CC5=NC=4)C4=CC=C(C=C43)OC)=CC2=C1 XVYFBCKOJVBDOF-UHFFFAOYSA-N 0.000 description 1
- HOOLUHYVJBFGFY-UHFFFAOYSA-N 2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-quinolin-8-ylacetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C5=NC=CC=C5C=CC=4)C4=CC=C(C=C43)OC)=CC2=C1 HOOLUHYVJBFGFY-UHFFFAOYSA-N 0.000 description 1
- SYQBBYQZKLRCRP-UHFFFAOYSA-N 2-[cyclopropyl-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]amino]acetaldehyde Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1N(CC=O)C1CC1 SYQBBYQZKLRCRP-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- VTXWAVDGZZPPIO-UHFFFAOYSA-N 2-but-3-enylpyrazine Chemical compound C=CCCC1=CN=CC=N1 VTXWAVDGZZPPIO-UHFFFAOYSA-N 0.000 description 1
- YMQRPXBBBOXHNZ-UHFFFAOYSA-N 2-chloro-1-morpholin-4-ylethanone Chemical compound ClCC(=O)N1CCOCC1 YMQRPXBBBOXHNZ-UHFFFAOYSA-N 0.000 description 1
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- BGRKDLVBPMCBJW-UHFFFAOYSA-N 2-ethyltetrazole Chemical compound CCN1N=CN=N1 BGRKDLVBPMCBJW-UHFFFAOYSA-N 0.000 description 1
- FURHRJBOFNDYTG-UHFFFAOYSA-N 2-fluoroethanamine Chemical compound NCCF FURHRJBOFNDYTG-UHFFFAOYSA-N 0.000 description 1
- LHMREMKFHPVFTH-UHFFFAOYSA-N 2-iodo-1-(4-methylphenyl)sulfonyl-4-phenylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(C=3C=CC=CC=3)=C2C=C1I LHMREMKFHPVFTH-UHFFFAOYSA-N 0.000 description 1
- QSQSIQIRMQFSSQ-UHFFFAOYSA-N 2-iodo-1-(4-methylphenyl)sulfonyl-5-phenylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=C(C=3C=CC=CC=3)C=C2C=C1I QSQSIQIRMQFSSQ-UHFFFAOYSA-N 0.000 description 1
- KHMGYVLYIXEUCL-UHFFFAOYSA-N 2-iodo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1I KHMGYVLYIXEUCL-UHFFFAOYSA-N 0.000 description 1
- ZSMJMLCFRNJKJN-UHFFFAOYSA-N 2-iodo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine-4-carbonitrile Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(C#N)=C2C=C1I ZSMJMLCFRNJKJN-UHFFFAOYSA-N 0.000 description 1
- YSJJXKLCMMTFAW-UHFFFAOYSA-N 2-iodo-3-methyl-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=NC=CC=C2C(C)=C(I)N1S(=O)(=O)C1=CC=C(C)C=C1 YSJJXKLCMMTFAW-UHFFFAOYSA-N 0.000 description 1
- WASROUXPXXNPSX-UHFFFAOYSA-N 2-iodo-4-methoxy-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound IC1=CC=2C(OC)=CC=NC=2N1S(=O)(=O)C1=CC=C(C)C=C1 WASROUXPXXNPSX-UHFFFAOYSA-N 0.000 description 1
- VXVWIRKAABQIGS-UHFFFAOYSA-N 2-isocyanatooxane Chemical compound O=C=NC1CCCCO1 VXVWIRKAABQIGS-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 description 1
- MMLMJZNNELPPNV-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine-3-carbaldehyde Chemical compound N1C2=NC=CC=C2C(C=O)=C1C1=CC=CC=C1 MMLMJZNNELPPNV-UHFFFAOYSA-N 0.000 description 1
- OGCFKNMRJGBFPU-UHFFFAOYSA-N 2-phenyl-3-prop-1-enyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C=CC)=C1C1=CC=CC=C1 OGCFKNMRJGBFPU-UHFFFAOYSA-N 0.000 description 1
- ALSYTSCUTDAYIU-UHFFFAOYSA-N 2-pyridin-3-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CN=C1 ALSYTSCUTDAYIU-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- OSEQIDSFSBWXRE-UHFFFAOYSA-N 3,4-dimethoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC OSEQIDSFSBWXRE-UHFFFAOYSA-N 0.000 description 1
- FICAQKBMCKEFDI-UHFFFAOYSA-N 3,5-dimethyl-1,2-oxazole Chemical compound CC=1C=C(C)ON=1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 description 1
- GZLPFEYTAAXJCP-UHFFFAOYSA-N 3,5-dimethyl-1,2-oxazole-4-sulfonyl chloride Chemical compound CC1=NOC(C)=C1S(Cl)(=O)=O GZLPFEYTAAXJCP-UHFFFAOYSA-N 0.000 description 1
- ZJIMYQVUQOVGDU-UHFFFAOYSA-N 3,5-dimethyl-4-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,2-oxazole Chemical compound CC1=NOC(C)=C1C1=CC=NC2=C1C=CN2 ZJIMYQVUQOVGDU-UHFFFAOYSA-N 0.000 description 1
- ZORSIMYLDRIING-UHFFFAOYSA-N 3,5-dimethyl-4-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-4-yl]-1,2-oxazole Chemical compound CC1=NOC(C)=C1C1=CC=NC2=C1C=CN2S(=O)(=O)C1=CC=C(C)C=C1 ZORSIMYLDRIING-UHFFFAOYSA-N 0.000 description 1
- AMEPOOHICAMGGM-UHFFFAOYSA-N 3-(1,3-dioxan-2-yl)benzonitrile Chemical compound N#CC1=CC=CC(C2OCCCO2)=C1 AMEPOOHICAMGGM-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- ZOOQBROEQHMAKJ-UHFFFAOYSA-N 3-(4-chloro-1h-pyrrolo[2,3-b]pyridin-2-yl)-n-(1-hydroxy-2-methylpropan-2-yl)-1-methylindole-5-carboxamide Chemical compound C12=CC(C(=O)NC(C)(C)CO)=CC=C2N(C)C=C1C1=CC2=C(Cl)C=CN=C2N1 ZOOQBROEQHMAKJ-UHFFFAOYSA-N 0.000 description 1
- BYVKEXFULGWIKG-UHFFFAOYSA-N 3-(4-cyano-1h-pyrrolo[2,3-b]pyridin-2-yl)-n-(1-hydroxy-2-methylpropan-2-yl)-1-methylindole-5-carboxamide Chemical compound C12=CC(C(=O)NC(C)(C)CO)=CC=C2N(C)C=C1C1=CC2=C(C#N)C=CN=C2N1 BYVKEXFULGWIKG-UHFFFAOYSA-N 0.000 description 1
- RBLSJYMBJFUGLJ-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-(4-methylpiperazin-1-yl)propan-1-one Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)N1CCN(C)CC1 RBLSJYMBJFUGLJ-UHFFFAOYSA-N 0.000 description 1
- SLCKPMRGVFIKEG-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-thiomorpholin-4-ylpropan-1-one Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)N1CCSCC1 SLCKPMRGVFIKEG-UHFFFAOYSA-N 0.000 description 1
- NFEUWAQACBASGR-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-(oxolan-2-ylmethyl)propanamide Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)NCC1CCCO1 NFEUWAQACBASGR-UHFFFAOYSA-N 0.000 description 1
- AVWZPCHWSSWCFA-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-phenylpropanamide Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)NC1=CC=CC=C1 AVWZPCHWSSWCFA-UHFFFAOYSA-N 0.000 description 1
- HUUVWAZMMHDJAT-UHFFFAOYSA-N 3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanoic acid Chemical compound C1=CN=C2NC(C=3N(CCC(O)=O)C4=CC=C(C=C4C=3)OC)=CC2=C1 HUUVWAZMMHDJAT-UHFFFAOYSA-N 0.000 description 1
- RKISGCJJBSZNEN-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-n,n-dimethylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)N(C)C)=C1C1=CC=C(C(C)(C)C)C=C1 RKISGCJJBSZNEN-UHFFFAOYSA-N 0.000 description 1
- AYJCGTRIBDXSHI-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]-n-methylpropanamide Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C1=CC=C(C(C)(C)C)C=C1 AYJCGTRIBDXSHI-UHFFFAOYSA-N 0.000 description 1
- IZJXUOPCDJBMST-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanenitrile Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCC#N)C2=NC=CN=C2N1 IZJXUOPCDJBMST-UHFFFAOYSA-N 0.000 description 1
- RDGODMUTJJJLBX-UHFFFAOYSA-N 3-[6-(4-tert-butylphenyl)-5h-pyrrolo[2,3-b]pyrazin-7-yl]propanoic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=C(CCC(O)=O)C2=NC=CN=C2N1 RDGODMUTJJJLBX-UHFFFAOYSA-N 0.000 description 1
- GAGJMOQGABUOBK-UHFFFAOYSA-N 3-aminopropanamide;hydrochloride Chemical compound Cl.NCCC(N)=O GAGJMOQGABUOBK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AZYVXIPPLYPYNG-UHFFFAOYSA-N 3-bromo-5,6-dimethoxyindole-1-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC2=C1N(C(O)=O)C=C2Br AZYVXIPPLYPYNG-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- KLXSUMLEPNAZFK-UHFFFAOYSA-N 3-methoxybenzonitrile Chemical compound COC1=CC=CC(C#N)=C1 KLXSUMLEPNAZFK-UHFFFAOYSA-N 0.000 description 1
- UAGWUCCOKDIIDM-UHFFFAOYSA-N 3-methyl-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=NC=CC=C2C(C)=CN1S(=O)(=O)C1=CC=C(C)C=C1 UAGWUCCOKDIIDM-UHFFFAOYSA-N 0.000 description 1
- PKZDPOGLGBWEGP-UHFFFAOYSA-N 3-methyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CC=C2C(C)=CNC2=N1 PKZDPOGLGBWEGP-UHFFFAOYSA-N 0.000 description 1
- UPAYIGZHWMYXCV-UHFFFAOYSA-N 3-methyl-2-(4-methylphenyl)-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CC=C(C)C=C1 UPAYIGZHWMYXCV-UHFFFAOYSA-N 0.000 description 1
- UGBJLTPTFVECSC-UHFFFAOYSA-N 3-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CC=CC=C1 UGBJLTPTFVECSC-UHFFFAOYSA-N 0.000 description 1
- WOSGPBFDGVRZKT-UHFFFAOYSA-N 3-methyl-6-phenyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC(C)=CN=C2C=C1C1=CC=CC=C1 WOSGPBFDGVRZKT-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- NLGQFNUTLPSVAW-UHFFFAOYSA-N 4-(1,3-dioxan-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1OCCCO1 NLGQFNUTLPSVAW-UHFFFAOYSA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- CNJGCQXKBAUFNA-UHFFFAOYSA-N 4-(3-methyl-1h-pyrrolo[2,3-b]pyridin-2-yl)benzoic acid Chemical compound N1C2=NC=CC=C2C(C)=C1C1=CC=C(C(O)=O)C=C1 CNJGCQXKBAUFNA-UHFFFAOYSA-N 0.000 description 1
- LZAYOZUFUAMFLD-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-hydroxypiperidine Chemical compound C=1C=C(Cl)C=CC=1C1(O)CCNCC1 LZAYOZUFUAMFLD-UHFFFAOYSA-N 0.000 description 1
- IMFTXEPMOHQTGC-UHFFFAOYSA-N 4-(4-cyanophenyl)piperazine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCN1C1=CC=C(C#N)C=C1 IMFTXEPMOHQTGC-UHFFFAOYSA-N 0.000 description 1
- QYBXZYYECZFQRX-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)benzoic acid Chemical class C1=CC(C(=O)O)=CC=C1CN1CCOCC1 QYBXZYYECZFQRX-UHFFFAOYSA-N 0.000 description 1
- XWHIXOMWXCHJPP-UHFFFAOYSA-N 4-(trifluoromethoxy)benzonitrile Chemical compound FC(F)(F)OC1=CC=C(C#N)C=C1 XWHIXOMWXCHJPP-UHFFFAOYSA-N 0.000 description 1
- RMSBSMVCSMWZST-UHFFFAOYSA-N 4-[(2-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)methyl]morpholine Chemical compound C=1C=CC=CC=1C=1NC2=NC=CC=C2C=1CN1CCOCC1 RMSBSMVCSMWZST-UHFFFAOYSA-N 0.000 description 1
- FCYQHFZWUANRNW-UHFFFAOYSA-N 4-[2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-4-yl]morpholine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=C(N3CCOCC3)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 FCYQHFZWUANRNW-UHFFFAOYSA-N 0.000 description 1
- YJKOKOAXYWZUHF-UHFFFAOYSA-N 4-[2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetyl]piperazin-2-one Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1CC(=O)N1CCNC(=O)C1 YJKOKOAXYWZUHF-UHFFFAOYSA-N 0.000 description 1
- QMXXYNQIJANUME-UHFFFAOYSA-N 4-[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]-1-methylpiperazin-2-one Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCN(C)C(=O)C1 QMXXYNQIJANUME-UHFFFAOYSA-N 0.000 description 1
- JCTPCFDGUQRJON-UHFFFAOYSA-N 4-[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]-3,3-dimethylpiperazin-2-one Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCNC(=O)C1(C)C JCTPCFDGUQRJON-UHFFFAOYSA-N 0.000 description 1
- ZKAWDAWXSOGKLM-UHFFFAOYSA-N 4-[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]piperazin-2-one Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCNC(=O)C1 ZKAWDAWXSOGKLM-UHFFFAOYSA-N 0.000 description 1
- GJVDGOMCEFWOID-UHFFFAOYSA-N 4-[4-(5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]piperazine-1-carboxylic acid Chemical compound C1CN(C(=O)O)CCN1C1=CC=C(C=2NC3=NC=CN=C3C=2)C=C1 GJVDGOMCEFWOID-UHFFFAOYSA-N 0.000 description 1
- PIEQCNJZKUDYST-UHFFFAOYSA-N 4-[6-(2-tert-butylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]butan-2-one Chemical compound C(C)(C)(C)C1=C(C=CC=C1)C1=C(C=2C(=NC=CN2)N1)CCC(C)=O PIEQCNJZKUDYST-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- RSGFDIWQURPTQL-UHFFFAOYSA-N 4-methoxy-2-(5-methoxy-1-methylindol-3-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C12=CC(OC)=CC=C2N(C)C=C1C1=CC2=C(OC)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 RSGFDIWQURPTQL-UHFFFAOYSA-N 0.000 description 1
- XDJAAZYHCCRJOK-UHFFFAOYSA-N 4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1 XDJAAZYHCCRJOK-UHFFFAOYSA-N 0.000 description 1
- RPVGEEHGKIFQFO-UHFFFAOYSA-N 4-methylsulfanylbenzonitrile Chemical compound CSC1=CC=C(C#N)C=C1 RPVGEEHGKIFQFO-UHFFFAOYSA-N 0.000 description 1
- ULDUNXDRDOJMJZ-UHFFFAOYSA-N 4-nitro-1h-pyrrolo[2,3-b]pyridine Chemical compound [O-][N+](=O)C1=CC=NC2=C1C=CN2 ULDUNXDRDOJMJZ-UHFFFAOYSA-N 0.000 description 1
- VTDLIXTUIXEFID-UHFFFAOYSA-N 4-pyridin-3-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1C1=CC=CN=C1 VTDLIXTUIXEFID-UHFFFAOYSA-N 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- CUTDHMHDGHQIED-UHFFFAOYSA-N 5,6,7,8-tetrahydroindolizine-1-carbonitrile Chemical compound C1CCCC2=C(C#N)C=CN21 CUTDHMHDGHQIED-UHFFFAOYSA-N 0.000 description 1
- QODBZRNBPUPLEZ-UHFFFAOYSA-N 5,6-dimethoxy-1h-indole Chemical compound C1=C(OC)C(OC)=CC2=C1NC=C2 QODBZRNBPUPLEZ-UHFFFAOYSA-N 0.000 description 1
- QQMAJIRGKGWCEU-UHFFFAOYSA-N 5-(4-methylphenyl)sulfonyl-6-phenylpyrrolo[2,3-b]pyrazine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CN=C2C=C1C1=CC=CC=C1 QQMAJIRGKGWCEU-UHFFFAOYSA-N 0.000 description 1
- LPTVWZSQAIDCEB-UHFFFAOYSA-N 5-bromo-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CN=C2NC=CC2=C1 LPTVWZSQAIDCEB-UHFFFAOYSA-N 0.000 description 1
- FRWDASPBRXZPCF-UHFFFAOYSA-N 5-bromo-3-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=C(Br)C=C2C(C)=C1C1=CC=CC=C1 FRWDASPBRXZPCF-UHFFFAOYSA-N 0.000 description 1
- VMIYBJLJAHMDLZ-UHFFFAOYSA-N 5-methoxy-1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-6-ol Chemical compound C=1N(C)C=2C=C(O)C(OC)=CC=2C=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 VMIYBJLJAHMDLZ-UHFFFAOYSA-N 0.000 description 1
- OFNAEHQJIMREFJ-UHFFFAOYSA-N 5-methoxy-1-methylindole-3-carbaldehyde Chemical compound COC1=CC=C2N(C)C=C(C=O)C2=C1 OFNAEHQJIMREFJ-UHFFFAOYSA-N 0.000 description 1
- DWAQDRSOVMLGRQ-UHFFFAOYSA-N 5-methoxyindole Chemical compound COC1=CC=C2NC=CC2=C1 DWAQDRSOVMLGRQ-UHFFFAOYSA-N 0.000 description 1
- TUWARWGEOHQXCO-UHFFFAOYSA-N 5-methoxyindole-3-carbaldehyde Chemical compound COC1=CC=C2NC=C(C=O)C2=C1 TUWARWGEOHQXCO-UHFFFAOYSA-N 0.000 description 1
- LQAFCJAXORNEHL-UHFFFAOYSA-N 5-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C2=CC(C)=CN=C2NC=1C1=CC=CC=C1 LQAFCJAXORNEHL-UHFFFAOYSA-N 0.000 description 1
- QHCBCVFLFCKZJA-UHFFFAOYSA-N 5-phenyl-1h-pyrrole-3-carbonitrile Chemical compound N#CC1=CNC(C=2C=CC=CC=2)=C1 QHCBCVFLFCKZJA-UHFFFAOYSA-N 0.000 description 1
- YGINNQXWHUWSHG-UHFFFAOYSA-N 6-(2-chlorophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound ClC1=CC=CC=C1C1=CC2=NC=CN=C2N1 YGINNQXWHUWSHG-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- VFKHBJJSGUYSDC-UHFFFAOYSA-N 6-(4-chlorophenyl)-5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CC(Cl)=CC=C1C1=CC2=NC=CN=C2N1 VFKHBJJSGUYSDC-UHFFFAOYSA-N 0.000 description 1
- UIHGKHKSOZXFRS-UHFFFAOYSA-N 6-(4-tert-butylphenyl)-7-(2-ethyltetrazol-5-yl)-5H-pyrrolo[2,3-b]pyrazine Chemical compound CCn1nnc(n1)-c1c([nH]c2nccnc12)-c1ccc(cc1)C(C)(C)C UIHGKHKSOZXFRS-UHFFFAOYSA-N 0.000 description 1
- AJBVUUPNIOLPFS-UHFFFAOYSA-N 6-chloro-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC(Cl)=CC=C2C=C1C1=CC=CC=C1 AJBVUUPNIOLPFS-UHFFFAOYSA-N 0.000 description 1
- KILYBYFBRWDGTM-UHFFFAOYSA-N 6-chloro-4-methyl-2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound C=1C=2C(C)=CC(Cl)=NC=2NC=1C1=CC=CC=C1 KILYBYFBRWDGTM-UHFFFAOYSA-N 0.000 description 1
- NNXKRJSTOZGIFL-UHFFFAOYSA-N 6-methoxy-1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-ol Chemical compound C1=2C=C(O)C(OC)=CC=2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 NNXKRJSTOZGIFL-UHFFFAOYSA-N 0.000 description 1
- PDSPDGYZVUBBSI-UHFFFAOYSA-N 6-methoxy-1-methyl-5-phenylmethoxyindole Chemical compound CN1C=CC2=CC(=C(C=C12)OC)OCC1=CC=CC=C1 PDSPDGYZVUBBSI-UHFFFAOYSA-N 0.000 description 1
- XDLZHWUPJHWVFK-UHFFFAOYSA-N 6-methoxy-5-phenylmethoxy-1h-indole Chemical compound COC1=CC=2NC=CC=2C=C1OCC1=CC=CC=C1 XDLZHWUPJHWVFK-UHFFFAOYSA-N 0.000 description 1
- QLBVJDQLXOSSMT-UHFFFAOYSA-N 7-methyl-6-phenyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(C)=C1C1=CC=CC=C1 QLBVJDQLXOSSMT-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 102000003989 Aurora kinases Human genes 0.000 description 1
- 108090000433 Aurora kinases Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- YDGFIVXHKKKFLB-UHFFFAOYSA-M C(=O)N1C(CCCC1)C(=O)[O-].[Na+].C=1(C=CN2CCCCC12)C#N Chemical compound C(=O)N1C(CCCC1)C(=O)[O-].[Na+].C=1(C=CN2CCCCC12)C#N YDGFIVXHKKKFLB-UHFFFAOYSA-M 0.000 description 1
- OXHRQGXZQHXOAE-UHFFFAOYSA-M C(C)(=O)OC(C)=O.C(=O)N1C(CCCC1)C(=O)[O-].[Na+] Chemical compound C(C)(=O)OC(C)=O.C(=O)N1C(CCCC1)C(=O)[O-].[Na+] OXHRQGXZQHXOAE-UHFFFAOYSA-M 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- IUIJQJGEIGFGIM-UHFFFAOYSA-N C1=CC(Br)=CC=C1C(N1)=CN=C2C1=CC=N2 Chemical compound C1=CC(Br)=CC=C1C(N1)=CN=C2C1=CC=N2 IUIJQJGEIGFGIM-UHFFFAOYSA-N 0.000 description 1
- REZOELXZPYEEAV-UHFFFAOYSA-N C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1 Chemical compound C1=CN=C2NC(C3=CNC4=CC=C(C=C43)OC)=CC2=C1 REZOELXZPYEEAV-UHFFFAOYSA-N 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- HNVNNYOHPQQUTC-UHFFFAOYSA-N CN(C(=O)C=1C=C2C(=CN(C2=CC1)C)C1=CC=2C(=NC=CN2)N1)C.CNC Chemical compound CN(C(=O)C=1C=C2C(=CN(C2=CC1)C)C1=CC=2C(=NC=CN2)N1)C.CNC HNVNNYOHPQQUTC-UHFFFAOYSA-N 0.000 description 1
- GXVDNCRRMAKOMX-UHFFFAOYSA-N CN(C=C(C1=CC2=CC=CN=C2N1)C1=C2)C1=CC=C2C(O)=O.OCCNCCO Chemical compound CN(C=C(C1=CC2=CC=CN=C2N1)C1=C2)C1=CC=C2C(O)=O.OCCNCCO GXVDNCRRMAKOMX-UHFFFAOYSA-N 0.000 description 1
- QEROMLQIOWGBGM-UHFFFAOYSA-N COC(=O)C=1C=C2C(=CNC2=CC1)C1=CC=2C(=NC=CC2)N1S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound COC(=O)C=1C=C2C(=CNC2=CC1)C1=CC=2C(=NC=CC2)N1S(=O)(=O)C1=CC=C(C)C=C1 QEROMLQIOWGBGM-UHFFFAOYSA-N 0.000 description 1
- HCYBNZDJPHYOOA-UHFFFAOYSA-N COC=1C=C2C(=CN(C2=CC1)C)C=O.COC=1C=C2C(=CN(C2=CC1)C)C#N Chemical compound COC=1C=C2C(=CN(C2=CC1)C)C=O.COC=1C=C2C(=CN(C2=CC1)C)C#N HCYBNZDJPHYOOA-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- NAFUHLFCCFNSKU-UHFFFAOYSA-N Cl.Cl.Cl.Cl.Cl.C(C)N(CC)CC Chemical compound Cl.Cl.Cl.Cl.Cl.C(C)N(CC)CC NAFUHLFCCFNSKU-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 206010062639 Herpes dermatitis Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 description 1
- 101000803266 Homo sapiens B-cell linker protein Proteins 0.000 description 1
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- UVPSSGJTBLNVRE-UHFFFAOYSA-N Moniliformin Natural products O=C1C(OC)=CC(=O)C=2C1=C1C(=O)C(OC)=CC(=O)C1=CC=2 UVPSSGJTBLNVRE-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- JGCXCVWVUBSFAU-UHFFFAOYSA-N N-(2,3-dihydroxypropyl)-1H-indole-5-carboxamide Chemical compound OCC(O)CNC(=O)C1=CC=C2NC=CC2=C1 JGCXCVWVUBSFAU-UHFFFAOYSA-N 0.000 description 1
- AVNIZWFDYNPOMU-UHFFFAOYSA-N N-[1-(methylamino)-1-oxopropan-2-yl]-1H-indole-5-carboxamide Chemical compound CNC(=O)C(C)NC(=O)C1=CC=C2NC=CC2=C1 AVNIZWFDYNPOMU-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- HERQBQCPFNJHQQ-UHFFFAOYSA-N N1C=CC2=CC=CN=C12.CC1=CC=C(C=C1)S(=O)(=O)N1C=CC=2C1=NC=CC2 Chemical compound N1C=CC2=CC=CN=C12.CC1=CC=C(C=C1)S(=O)(=O)N1C=CC=2C1=NC=CC2 HERQBQCPFNJHQQ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRFZBPORIMJIRQ-UHFFFAOYSA-N OCC(C)(C)NC(=O)C=1C=C2C(=CN(C2=CC1)C)C=1CC=C2C(N1)=NC=C2 Chemical compound OCC(C)(C)NC(=O)C=1C=C2C(=CN(C2=CC1)C)C=1CC=C2C(N1)=NC=C2 GRFZBPORIMJIRQ-UHFFFAOYSA-N 0.000 description 1
- LTCCVMWRCUBOHU-UHFFFAOYSA-N OCC(C)(C)NC(=O)C=1C=C2C=CN(C2=CC1)C.CC(CC)O Chemical compound OCC(C)(C)NC(=O)C=1C=C2C=CN(C2=CC1)C.CC(CC)O LTCCVMWRCUBOHU-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000607000 Plesiomonas Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000038012 SFKs Human genes 0.000 description 1
- 108091008118 SFKs Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VJFCXIANBVZXLF-UHFFFAOYSA-N [1-(4-methylphenyl)sulfonylindol-2-yl] trifluoromethanesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=CC=CC=C2C=C1OS(=O)(=O)C(F)(F)F VJFCXIANBVZXLF-UHFFFAOYSA-N 0.000 description 1
- RNNYDDJNYXLBHB-UHFFFAOYSA-N [3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]-1h-indol-5-yl]carbamic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC=C2C=C1C1=CNC2=CC=C(NC(O)=O)C=C12 RNNYDDJNYXLBHB-UHFFFAOYSA-N 0.000 description 1
- NKDZWWAQJHMLCA-UHFFFAOYSA-N [4-[7-[3-(methylamino)-3-oxopropyl]-5h-pyrrolo[2,3-b]pyrazin-6-yl]phenyl] trifluoromethanesulfonate Chemical compound N1C2=NC=CN=C2C(CCC(=O)NC)=C1C1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1 NKDZWWAQJHMLCA-UHFFFAOYSA-N 0.000 description 1
- HVQUTNWOXNKNEK-UHFFFAOYSA-N [5-methoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]boronic acid Chemical compound COC1=CC=C2N(C(=O)OC(C)(C)C)C=C(B(O)O)C2=C1 HVQUTNWOXNKNEK-UHFFFAOYSA-N 0.000 description 1
- JCJQZZCYWOFHRR-UHFFFAOYSA-N [N].C(C)OC(CN1C=C(C2=CC(=CC=C12)OC)C1=CC=2C(=NC=CC2)N1S(=O)(=O)C1=CC=C(C)C=C1)=O Chemical compound [N].C(C)OC(CN1C=C(C2=CC(=CC=C12)OC)C1=CC=2C(=NC=CC2)N1S(=O)(=O)C1=CC=C(C)C=C1)=O JCJQZZCYWOFHRR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- VNEMVKOXLBIWTB-UHFFFAOYSA-N aminomethyl benzoate Chemical class NCOC(=O)C1=CC=CC=C1 VNEMVKOXLBIWTB-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000002152 aqueous-organic solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-N butynedioic acid Chemical compound OC(=O)C#CC(O)=O YTIVTFGABIZHHX-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- STNNHWPJRRODGI-UHFFFAOYSA-N carbonic acid;n,n-diethylethanamine Chemical compound [O-]C([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC STNNHWPJRRODGI-UHFFFAOYSA-N 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Chemical compound 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- PBGGNZZGJIKBMJ-UHFFFAOYSA-N di(propan-2-yl)azanide Chemical compound CC(C)[N-]C(C)C PBGGNZZGJIKBMJ-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- WGYNZBIFSWZNMA-UHFFFAOYSA-N dipropan-2-yl but-2-ynedioate Chemical compound CC(C)OC(=O)C#CC(=O)OC(C)C WGYNZBIFSWZNMA-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000017793 embryonic organ development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- GGSZYSPQSNAXFZ-UHFFFAOYSA-N ethyl 2-[5-methoxy-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-1-yl]acetate Chemical compound C12=CC(OC)=CC=C2N(CC(=O)OCC)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 GGSZYSPQSNAXFZ-UHFFFAOYSA-N 0.000 description 1
- DUVOZUPPHBRJJO-UHFFFAOYSA-N ethyl 2-isocyanatoacetate Chemical compound CCOC(=O)CN=C=O DUVOZUPPHBRJJO-UHFFFAOYSA-N 0.000 description 1
- NFSAVKIIBSNKGZ-UHFFFAOYSA-N ethyl 3-[1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indol-5-yl]propanoate Chemical compound C12=CC(CCC(=O)OCC)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 NFSAVKIIBSNKGZ-UHFFFAOYSA-N 0.000 description 1
- RJCGNNHKSNIUAT-UHFFFAOYSA-N ethyl 3-aminopropanoate;hydron;chloride Chemical compound Cl.CCOC(=O)CCN RJCGNNHKSNIUAT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 1
- ZQFYJHMUAWCEBH-UHFFFAOYSA-N furan-3-carbonitrile Chemical compound N#CC=1C=COC=1 ZQFYJHMUAWCEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002476 indolines Chemical class 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004247 indolizin-1-yl group Chemical group [H]C1=C([H])C(*)=C2C([H])=C([H])C([H])=C([H])N12 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GXXBVBVNGMCFIU-UHFFFAOYSA-N isoquinoline-3-carbonitrile Chemical compound C1=CC=C2C=NC(C#N)=CC2=C1 GXXBVBVNGMCFIU-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- JLLNVEWZLBARFN-UHFFFAOYSA-N methanesulfonic acid;2-(5-methoxy-1-methylindol-3-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)OC)=CC2=C1 JLLNVEWZLBARFN-UHFFFAOYSA-N 0.000 description 1
- UAWBKMRSNQHKOA-UHFFFAOYSA-N methanesulfonic acid;2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound CS(O)(=O)=O.C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 UAWBKMRSNQHKOA-UHFFFAOYSA-N 0.000 description 1
- HMSLTGXEUDAMOE-UHFFFAOYSA-N methanesulfonic acid;2-[5-methoxy-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]-1-morpholin-4-ylethanone Chemical compound CS(O)(=O)=O.C1=C(C=2NC3=NC=CN=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N1CCOCC1 HMSLTGXEUDAMOE-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- NDBQJIBNNUJNHA-DFWYDOINSA-N methyl (2s)-2-amino-3-hydroxypropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CO NDBQJIBNNUJNHA-DFWYDOINSA-N 0.000 description 1
- MDDFRDNMAPWTEM-UHFFFAOYSA-N methyl 1-(4-methylphenyl)sulfonyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indole-5-carboxylate Chemical compound COC(=O)C=1C=C2C(=CN(C2=CC1)S(=O)(=O)C1=CC=C(C)C=C1)C1=CC=2C(=NC=CC2)N1S(=O)(=O)C1=CC=C(C)C=C1 MDDFRDNMAPWTEM-UHFFFAOYSA-N 0.000 description 1
- OVYHABPMJWQIAZ-UHFFFAOYSA-N methyl 1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxylate Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)OC)=CC2=N1 OVYHABPMJWQIAZ-UHFFFAOYSA-N 0.000 description 1
- WVGUVNOCMJAHQR-UHFFFAOYSA-N methyl 1-methyl-3-[1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]indole-6-carboxylate Chemical compound C=1N(C)C2=CC(C(=O)OC)=CC=C2C=1C1=CC2=CC=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 WVGUVNOCMJAHQR-UHFFFAOYSA-N 0.000 description 1
- AYYOZKHMSABVRP-UHFFFAOYSA-N methyl 1h-indole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CNC2=C1 AYYOZKHMSABVRP-UHFFFAOYSA-N 0.000 description 1
- KXSYSWDIVYLYGF-UHFFFAOYSA-N methyl 2-[6-(4-tert-butylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-2-methyl-3-oxobutanoate Chemical compound COC(=O)C(C)(C(C)=O)c1c([nH]c2nccnc12)-c1ccc(cc1)C(C)(C)C KXSYSWDIVYLYGF-UHFFFAOYSA-N 0.000 description 1
- KCBDEKXPSQVLEP-UHFFFAOYSA-N methyl 2-[[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]amino]-3-methylpentanoate Chemical compound C12=CC(OC)=CC=C2N(CC(=O)NC(C(C)CC)C(=O)OC)C=C1C1=CC2=CC=CN=C2N1 KCBDEKXPSQVLEP-UHFFFAOYSA-N 0.000 description 1
- YPPMOQSQWQHRMK-UHFFFAOYSA-N methyl 3-(4-chloro-1h-pyrrolo[2,3-b]pyridin-2-yl)-1-methylindole-5-carboxylate Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)OC)=CC2=C1Cl YPPMOQSQWQHRMK-UHFFFAOYSA-N 0.000 description 1
- FGOZFBAWDDMQHB-UHFFFAOYSA-N methyl 3-(4-cyano-1h-pyrrolo[2,3-b]pyridin-2-yl)-1-methylindole-5-carboxylate Chemical compound C1=CN=C2NC(C3=CN(C)C4=CC=C(C=C43)C(=O)OC)=CC2=C1C#N FGOZFBAWDDMQHB-UHFFFAOYSA-N 0.000 description 1
- XOAQNGALOTYKLS-UHFFFAOYSA-N methyl 3-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]-1-methylindole-5-carboxylate Chemical compound COC(=O)C=1C=C2C(=CN(C2=CC1)C)C1=CC=2C(=NC=CC2C=2C(=NOC2C)C)N1S(=O)(=O)C1=CC=C(C)C=C1 XOAQNGALOTYKLS-UHFFFAOYSA-N 0.000 description 1
- IBFFABAKDBOXTA-UHFFFAOYSA-N methyl 3-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]-1H-indole-5-carboxylate Chemical compound COC(=O)C=1C=C2C(=CNC2=CC1)C1=CC=2C(=NC=CC2C=2C(=NOC2C)C)N1S(=O)(=O)C1=CC=C(C)C=C1 IBFFABAKDBOXTA-UHFFFAOYSA-N 0.000 description 1
- LNXUMJPAJXRUDJ-UHFFFAOYSA-N methyl 3-[4-chloro-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]-1-methylindole-5-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2N(C)C=C1C1=CC2=C(Cl)C=CN=C2N1S(=O)(=O)C1=CC=C(C)C=C1 LNXUMJPAJXRUDJ-UHFFFAOYSA-N 0.000 description 1
- GXUYEOPXCZLGDB-UHFFFAOYSA-N methyl 3-[4-methoxy-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-2-yl]-1-methylindole-5-carboxylate Chemical compound COC(=O)C=1C=C2C(=CN(C2=CC1)C)C1=CC=2C(=NC=CC2OC)N1S(=O)(=O)C1=CC=C(C)C=C1 GXUYEOPXCZLGDB-UHFFFAOYSA-N 0.000 description 1
- QCMDUUAPARGBIF-UHFFFAOYSA-N methyl 4-(3-methyl-1h-pyrrolo[2,3-b]pyridin-2-yl)benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1C1=C(C)C2=CC=CN=C2N1 QCMDUUAPARGBIF-UHFFFAOYSA-N 0.000 description 1
- JWPYKMVUNLCFIN-UHFFFAOYSA-N methyl 6-[[2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetyl]amino]hexanoate Chemical compound C12=CC(OC)=CC=C2N(CC(=O)NCCCCCC(=O)OC)C=C1C1=CC2=CC=CN=C2N1 JWPYKMVUNLCFIN-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- ZLADYZHDLCSTJV-UHFFFAOYSA-N methyl n-(2-hydroxyethyl)carbamate Chemical compound COC(=O)NCCO ZLADYZHDLCSTJV-UHFFFAOYSA-N 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- KGPQKNJSZNXOPV-UHFFFAOYSA-N moniliformin Chemical compound OC1=CC(=O)C1=O KGPQKNJSZNXOPV-UHFFFAOYSA-N 0.000 description 1
- LPWAKYISHIZIPO-UHFFFAOYSA-N morpholin-4-ylmethyl benzoate Chemical class C=1C=CC=CC=1C(=O)OCN1CCOCC1 LPWAKYISHIZIPO-UHFFFAOYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OFCCYDUUBNUJIB-UHFFFAOYSA-N n,n-diethylcarbamoyl chloride Chemical compound CCN(CC)C(Cl)=O OFCCYDUUBNUJIB-UHFFFAOYSA-N 0.000 description 1
- DQDHHXBVPTWVJC-UHFFFAOYSA-N n,n-dimethyl-1-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)methanamine Chemical compound N1C2=NC=CC=C2C(CN(C)C)=C1C1=CC=CC=C1 DQDHHXBVPTWVJC-UHFFFAOYSA-N 0.000 description 1
- RIYDZDVMOLPOSA-UHFFFAOYSA-N n-(1,3-dihydroxy-2-methylpropan-2-yl)-1-methyl-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(C)(CO)CO)=CC=C2N(C)C=C1C1=CC2=CC=CN=C2N1 RIYDZDVMOLPOSA-UHFFFAOYSA-N 0.000 description 1
- NUWVHJZFJTVFFF-UHFFFAOYSA-N n-(1-adamantyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC45CC6CC(CC(C6)C4)C5)C4=CC=C(C=C43)OC)=CC2=C1 NUWVHJZFJTVFFF-UHFFFAOYSA-N 0.000 description 1
- GQMCFEHNSZEBAH-UHFFFAOYSA-N n-(1-benzylsulfanyl-3-hydroxypropan-2-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(CO)CSCC1=CC=CC=C1 GQMCFEHNSZEBAH-UHFFFAOYSA-N 0.000 description 1
- APTYWMXFUGYVGM-UHFFFAOYSA-N n-(1-cyclohexylethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(C)C1CCCCC1 APTYWMXFUGYVGM-UHFFFAOYSA-N 0.000 description 1
- ZZNPIMREDONCNL-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide Chemical compound C12=CC(C(=O)NC(C)(C)CO)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 ZZNPIMREDONCNL-UHFFFAOYSA-N 0.000 description 1
- QLWVZFKXLGZRBW-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)-1-methyl-3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indole-5-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C12=CC(C(=O)NC(C)(C)CO)=CC=C2N(C)C=C1C1=CC2=NC=CN=C2N1 QLWVZFKXLGZRBW-UHFFFAOYSA-N 0.000 description 1
- GVZKRJYUUHPGOM-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)pyridine-4-carboxamide Chemical class OCC(C)(C)NC(=O)C1=CC=NC=C1 GVZKRJYUUHPGOM-UHFFFAOYSA-N 0.000 description 1
- KLUNYVGERQVDEL-UHFFFAOYSA-N n-(1-hydroxy-3-methylpentan-2-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C12=CC(OC)=CC=C2N(CC(=O)NC(CO)C(C)CC)C=C1C1=CC2=CC=CN=C2N1 KLUNYVGERQVDEL-UHFFFAOYSA-N 0.000 description 1
- RPQMMWNGEOEELN-UHFFFAOYSA-N n-(1-methoxypropan-2-yl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C12=CC(OC)=CC=C2N(CC(=O)NC(C)COC)C=C1C1=CC2=CC=CN=C2N1 RPQMMWNGEOEELN-UHFFFAOYSA-N 0.000 description 1
- PFJHVRHXIOUCAX-UHFFFAOYSA-N n-(2-hydroxy-2-methylpropyl)pyridine-4-carboxamide Chemical compound CC(C)(O)CNC(=O)C1=CC=NC=C1 PFJHVRHXIOUCAX-UHFFFAOYSA-N 0.000 description 1
- JGCBNDGUNFLGOT-UHFFFAOYSA-N n-(2-hydroxy-2-phenylethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCC(O)C1=CC=CC=C1 JGCBNDGUNFLGOT-UHFFFAOYSA-N 0.000 description 1
- NQGBDQFBNJWTKV-UHFFFAOYSA-N n-(2-hydroxy-2-phenylethyl)-3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanamide Chemical compound C=1C2=CC=CN=C2NC=1C1=CC2=CC(OC)=CC=C2N1CCC(=O)NCC(O)C1=CC=CC=C1 NQGBDQFBNJWTKV-UHFFFAOYSA-N 0.000 description 1
- WCHHHXDNCZWUCN-UHFFFAOYSA-N n-(2-hydroxyethyl)-3-[5-methoxy-2-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]propanamide Chemical compound C1=CN=C2NC(C=3N(CCC(=O)NCCO)C4=CC=C(C=C4C=3)OC)=CC2=C1 WCHHHXDNCZWUCN-UHFFFAOYSA-N 0.000 description 1
- LYIYYGXAFXQMMY-UHFFFAOYSA-N n-(3,3-dimethylbutyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NCCC(C)(C)C)C4=CC=C(C=C43)OC)=CC2=C1 LYIYYGXAFXQMMY-UHFFFAOYSA-N 0.000 description 1
- SWTRFAZOSVBCEQ-UHFFFAOYSA-N n-(3-bicyclo[2.2.1]heptanyl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CC=CN3CC(=O)NC3C4CCC(C4)C3)=CC2=C1 SWTRFAZOSVBCEQ-UHFFFAOYSA-N 0.000 description 1
- NMRKIHXDXKYQIK-UHFFFAOYSA-N n-(3-ethoxypropyl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetamide Chemical compound CCOCCCNC(=O)CN1C=CC=C1C1=CC2=CC=CN=C2N1 NMRKIHXDXKYQIK-UHFFFAOYSA-N 0.000 description 1
- RAQMCUQHYAXSAQ-UHFFFAOYSA-N n-(3-ethoxypropyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C12=CC(OC)=CC=C2N(CC(=O)NCCCOCC)C=C1C1=CC2=CC=CN=C2N1 RAQMCUQHYAXSAQ-UHFFFAOYSA-N 0.000 description 1
- XPWCAGOODXOSQF-UHFFFAOYSA-N n-(3-hydroxypropyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NCCCO)C4=CC=C(C=C43)OC)=CC2=C1 XPWCAGOODXOSQF-UHFFFAOYSA-N 0.000 description 1
- RUWBQGYDDYKZBO-UHFFFAOYSA-N n-(3-imidazol-1-ylpropyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCCN1C=CN=C1 RUWBQGYDDYKZBO-UHFFFAOYSA-N 0.000 description 1
- UAQOPUOGTVVJOG-UHFFFAOYSA-N n-(3-methoxyphenyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound COC1=CC=CC(NC(=O)CN2C3=CC=C(OC)C=C3C(C=3NC4=NC=CC=C4C=3)=C2)=C1 UAQOPUOGTVVJOG-UHFFFAOYSA-N 0.000 description 1
- BWDHNWLTLZYVPZ-UHFFFAOYSA-N n-(4-cyclohexylphenyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC(C=C1)=CC=C1C1CCCCC1 BWDHNWLTLZYVPZ-UHFFFAOYSA-N 0.000 description 1
- SDXMJIPVQXTKHA-UHFFFAOYSA-N n-(cyclohexylmethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCC1CCCCC1 SDXMJIPVQXTKHA-UHFFFAOYSA-N 0.000 description 1
- QDVFRJLKYWBIGS-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-propylacetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CCC)CC1CC1 QDVFRJLKYWBIGS-UHFFFAOYSA-N 0.000 description 1
- BKYWCHNTPSJIPB-UHFFFAOYSA-N n-(furan-2-ylmethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCC1=CC=CO1 BKYWCHNTPSJIPB-UHFFFAOYSA-N 0.000 description 1
- OWWPANZSJZYUNE-UHFFFAOYSA-N n-(oxolan-2-ylmethyl)-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetamide Chemical compound C1=CC=C(C=2NC3=NC=CC=C3C=2)N1CC(=O)NCC1CCCO1 OWWPANZSJZYUNE-UHFFFAOYSA-N 0.000 description 1
- PFSVZOCOJUBWKM-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NCCC=4C5=CC=CC=C5NC=4)C4=CC=C(C=C43)OC)=CC2=C1 PFSVZOCOJUBWKM-UHFFFAOYSA-N 0.000 description 1
- OTLAWGHCSSWALL-UHFFFAOYSA-N n-[2-(2-phenyl-1h-pyrrolo[2,3-b]pyridin-3-yl)ethyl]acetamide Chemical compound N1C2=NC=CC=C2C(CCNC(=O)C)=C1C1=CC=CC=C1 OTLAWGHCSSWALL-UHFFFAOYSA-N 0.000 description 1
- JITNVCCYVFHUPF-UHFFFAOYSA-N n-[2-(4-hydroxyphenyl)ethyl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCC1=CC=C(O)C=C1 JITNVCCYVFHUPF-UHFFFAOYSA-N 0.000 description 1
- CKWDSZDPLPOMIS-UHFFFAOYSA-N n-[2-(cyclohexen-1-yl)ethyl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NCCC1=CCCCC1 CKWDSZDPLPOMIS-UHFFFAOYSA-N 0.000 description 1
- UCEFCADDMARKNY-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-methylacetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)N(C)CCN(C)C)C4=CC=C(C=C43)OC)=CC2=C1 UCEFCADDMARKNY-UHFFFAOYSA-N 0.000 description 1
- BNUZXVCJKJCTDJ-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)propyl]-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetamide Chemical compound C1CN(C)CCN1CCCNC(=O)CN1C(C=2NC3=NC=CC=C3C=2)=CC=C1 BNUZXVCJKJCTDJ-UHFFFAOYSA-N 0.000 description 1
- YXWQRVXVYKXVBJ-UHFFFAOYSA-N n-[4-(diethylaminomethyl)phenyl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CC(CN(CC)CC)=CC=C1NC(=O)CN1C2=CC=C(OC)C=C2C(C=2NC3=NC=CC=C3C=2)=C1 YXWQRVXVYKXVBJ-UHFFFAOYSA-N 0.000 description 1
- YOBJQIPCIAHXII-UHFFFAOYSA-N n-[5-(diethylamino)pentan-2-yl]-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C12=CC(OC)=CC=C2N(CC(=O)NC(C)CCCN(CC)CC)C=C1C1=CC2=CC=CN=C2N1 YOBJQIPCIAHXII-UHFFFAOYSA-N 0.000 description 1
- FVDAMNUVJJJNSL-UHFFFAOYSA-N n-benzyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]-n-methylacetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(C)CC1=CC=CC=C1 FVDAMNUVJJJNSL-UHFFFAOYSA-N 0.000 description 1
- BDXRRHMLJWUPEC-UHFFFAOYSA-N n-benzyl-n-(2-hydroxyethyl)-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)N(CCO)CC1=CC=CC=C1 BDXRRHMLJWUPEC-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- JEFZUFURTMXHJS-UHFFFAOYSA-N n-cyclobutyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CCC1 JEFZUFURTMXHJS-UHFFFAOYSA-N 0.000 description 1
- UGAWDKCMHODVKI-UHFFFAOYSA-N n-cyclohexyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CCCCC1 UGAWDKCMHODVKI-UHFFFAOYSA-N 0.000 description 1
- PQQLLFPXCAFOIK-UHFFFAOYSA-N n-cyclopentyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CCCC1 PQQLLFPXCAFOIK-UHFFFAOYSA-N 0.000 description 1
- AHOFWEBRHKZIDP-UHFFFAOYSA-N n-cyclopropyl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=C(C=2NC3=NC=CC=C3C=2)C2=CC(OC)=CC=C2N1CC(=O)NC1CC1 AHOFWEBRHKZIDP-UHFFFAOYSA-N 0.000 description 1
- FONFOCGAFSGSEP-UHFFFAOYSA-N n-isoquinolin-1-yl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C5=CC=CC=C5C=CN=4)C4=CC=C(C=C43)OC)=CC2=C1 FONFOCGAFSGSEP-UHFFFAOYSA-N 0.000 description 1
- UVNXCLKSJRVXIO-UHFFFAOYSA-N n-isoquinolin-5-yl-2-[5-methoxy-3-(1h-pyrrolo[2,3-b]pyridin-2-yl)indol-1-yl]acetamide Chemical compound C1=CN=C2NC(C3=CN(CC(=O)NC=4C5=CC=NC=C5C=CC=4)C4=CC=C(C=C43)OC)=CC2=C1 UVNXCLKSJRVXIO-UHFFFAOYSA-N 0.000 description 1
- SLWHSKNWMOGTON-UHFFFAOYSA-N n-pentan-2-yl-2-[2-(1h-pyrrolo[2,3-b]pyridin-2-yl)pyrrol-1-yl]acetamide Chemical compound CCCC(C)NC(=O)CN1C=CC=C1C1=CC2=CC=CN=C2N1 SLWHSKNWMOGTON-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- WDXARTMCIRVMAE-UHFFFAOYSA-N quinoline-2-carbonitrile Chemical compound C1=CC=CC2=NC(C#N)=CC=C21 WDXARTMCIRVMAE-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- BKEVUZHCAQICFT-UHFFFAOYSA-M sodium;1-formylpiperidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCCCN1C=O BKEVUZHCAQICFT-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 230000024477 spindle organization Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- DEVZMRRLUDQEHL-UHFFFAOYSA-N tert-butyl-dimethyl-[2-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]ethoxy]silane Chemical compound C12=CC=CC=C2N(CCO[Si](C)(C)C(C)(C)C)C=C1C1=CC2=NC=CN=C2N1 DEVZMRRLUDQEHL-UHFFFAOYSA-N 0.000 description 1
- IJAGVSQDJDQRIM-UHFFFAOYSA-N tert-butyl-dimethyl-[3-[3-(5h-pyrrolo[2,3-b]pyrazin-6-yl)indol-1-yl]propoxy]silane Chemical compound C12=CC=CC=C2N(CCCO[Si](C)(C)C(C)(C)C)C=C1C1=CC2=NC=CN=C2N1 IJAGVSQDJDQRIM-UHFFFAOYSA-N 0.000 description 1
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- ZXUCBXRTRRIBSO-UHFFFAOYSA-L tetrabutylazanium;sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC ZXUCBXRTRRIBSO-UHFFFAOYSA-L 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- MPSUGQWRVNRJEE-UHFFFAOYSA-N triazol-1-amine Chemical compound NN1C=CN=N1 MPSUGQWRVNRJEE-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- GSQBIOQCECCMOQ-UHFFFAOYSA-N β-alanine ethyl ester Chemical compound CCOC(=O)CCN GSQBIOQCECCMOQ-UHFFFAOYSA-N 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0115109.1A GB0115109D0 (en) | 2001-06-21 | 2001-06-21 | Chemical compounds |
| US30025701P | 2001-06-22 | 2001-06-22 | |
| PCT/GB2002/002799 WO2003000688A1 (en) | 2001-06-21 | 2002-06-20 | Azaindoles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534826A JP2004534826A (ja) | 2004-11-18 |
| JP2004534826A5 JP2004534826A5 (enExample) | 2006-01-05 |
| JP4409938B2 true JP4409938B2 (ja) | 2010-02-03 |
Family
ID=9917016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003507091A Expired - Fee Related JP4409938B2 (ja) | 2001-06-21 | 2002-06-20 | アザインドール |
Country Status (37)
Families Citing this family (235)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1615873A (zh) | 1999-12-24 | 2005-05-18 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| CA2495216A1 (en) | 2002-08-12 | 2004-02-19 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| SE0202463D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| US20050043212A1 (en) * | 2002-10-09 | 2005-02-24 | Ford Kirschenbaum | Differential inhibition of p38 map kinase isoforms |
| US20050288299A1 (en) * | 2002-10-09 | 2005-12-29 | Mavunkel Babu J | Azaindole derivatives as inhibitors of p38 kinase |
| CN1713910A (zh) * | 2002-10-09 | 2005-12-28 | 西奥斯股份有限公司 | 作为p38激酶抑制剂的氮杂吲哚衍生物 |
| US7098231B2 (en) * | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| GB0305142D0 (en) * | 2003-03-06 | 2003-04-09 | Eisai London Res Lab Ltd | Synthesis |
| SE0301372D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| AU2004275694B2 (en) * | 2003-06-30 | 2008-03-06 | Bizbiotech Co., Ltd. | Compounds, compositions and methods |
| US7202363B2 (en) | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| WO2005056547A2 (en) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| KR20120091276A (ko) * | 2004-02-20 | 2012-08-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이러스 폴리머라제 억제제 |
| PT1730146E (pt) * | 2004-03-30 | 2011-07-11 | Vertex Pharma | Azaindoles úteis como inibidores de jak e outras proteínas quinases |
| FR2868422B1 (fr) | 2004-03-31 | 2006-07-14 | Aventis Pharma Sa | Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| WO2005097129A2 (en) * | 2004-04-05 | 2005-10-20 | Takeda Pharmaceutical Company Limited | 6-azaindole compound |
| WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| KR20070053237A (ko) * | 2004-07-27 | 2007-05-23 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 피롤로-피리딘 키나제 조절제 |
| CA2573538C (en) | 2004-07-30 | 2014-11-25 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| BRPI0514094A (pt) * | 2004-08-02 | 2008-05-27 | Osi Pharm Inc | composto, composição, e, método de tratamento de distúrbio hiperproliferativo |
| EP1778669A2 (en) | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| JP2008510792A (ja) * | 2004-08-26 | 2008-04-10 | ファイザー・インク | タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
| FR2876103B1 (fr) | 2004-10-01 | 2008-02-22 | Aventis Pharma Sa | Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| MY179032A (en) * | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| EP1814882A1 (en) * | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| JP4954086B2 (ja) * | 2004-12-08 | 2012-06-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 1h−ピロロ[2,3−b]ピリジン |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| US7786113B2 (en) * | 2004-12-23 | 2010-08-31 | Hoffman-La Roche Inc. | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents |
| EP1874769B1 (de) * | 2005-04-25 | 2011-09-14 | Merck Patent GmbH | Neuartige aza-heterozyklen als kinase-inhibitoren |
| FR2884821B1 (fr) * | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
| AU2006343808B2 (en) | 2005-05-20 | 2012-03-29 | Mirati Therapeutics, Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
| CA2608726C (en) | 2005-05-20 | 2013-07-09 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
| EP1881983B1 (en) | 2005-05-20 | 2012-01-11 | Vertex Pharmaceuticals, Inc. | Pyrrolopyridines useful as inhibitors of protein kinase |
| JP2008543855A (ja) | 2005-06-13 | 2008-12-04 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 変形性骨疾患を処置するための方法および組成物 |
| EP1734251B1 (en) * | 2005-06-17 | 2007-01-24 | MAGNETI MARELLI POWERTRAIN S.p.A. | Fuel injector |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| KR101142363B1 (ko) * | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| EP1915378A4 (en) * | 2005-08-12 | 2009-07-22 | Boehringer Ingelheim Int | VIRUS POLYMERASE INHIBITORS |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US7576218B2 (en) | 2005-10-11 | 2009-08-18 | Chemocentryx, Inc. | 4-phenylpiperdine-pyrazole CCR1 antagonists |
| US7371862B2 (en) | 2005-11-11 | 2008-05-13 | Pfizer Italia S.R.L. | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP2009515984A (ja) | 2005-11-15 | 2009-04-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なアザインダゾール |
| EP1963320A1 (en) * | 2005-12-07 | 2008-09-03 | OSI Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
| DK3184526T3 (en) | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| EP1968961A2 (en) | 2005-12-21 | 2008-09-17 | Decode Genetics EHF | Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation |
| NZ601687A (en) | 2006-01-17 | 2014-03-28 | Vertex Pharma | Azaindoles useful as inhibitors of janus kinases |
| CN101466676B (zh) * | 2006-04-12 | 2012-07-18 | 默沙东公司 | 吡啶基酰胺类t-型钙通道拮抗剂 |
| PL2026775T3 (pl) * | 2006-05-09 | 2015-12-31 | Novaremed Ltd | Zastosowanie inhibitorów kinazy tyrozynowej Syk w leczeniu komórkowych zaburzeń proliferacyjnych |
| US8604031B2 (en) * | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| GB0617161D0 (en) * | 2006-08-31 | 2006-10-11 | Vernalis R&D Ltd | Enzyme inhibitors |
| CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
| JP2010505961A (ja) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| CA2673472A1 (en) | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo) [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| PE20081581A1 (es) * | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| TW200833711A (en) * | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
| BRPI0809542A8 (pt) | 2007-03-29 | 2015-09-15 | Asubio Pharma Co Ltd | Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos |
| DK2740731T3 (en) | 2007-06-13 | 2016-04-11 | Incyte Holdings Corp | CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| CA2701594C (en) | 2007-10-24 | 2014-02-18 | Merck Sharp & Dohme Corp. | Heterocycle phenyl amide t-type calcium channel antagonists |
| AU2008317352A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Heterocycle amide T-type calcium channel antagonists |
| EP2247595B1 (en) | 2008-02-25 | 2011-07-20 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
| ES2372908T3 (es) | 2008-02-25 | 2012-01-27 | F. Hoffmann-La Roche Ag | Inhibidores de la pirrolopirazina quinasa. |
| KR20100114095A (ko) | 2008-02-25 | 2010-10-22 | 에프. 호프만-라 로슈 아게 | 피롤로피라진 키나아제 저해제 |
| CN101952294B (zh) | 2008-02-25 | 2014-11-26 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| PL2247592T3 (pl) | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
| KR20100137495A (ko) | 2008-03-05 | 2010-12-30 | 메틸진 인코포레이티드 | 단백질 티로신 키나아제 활성의 억제제 |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| PL2300013T5 (pl) | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| EP2313411A1 (en) * | 2008-06-10 | 2011-04-27 | Plexxikon, Inc. | 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor |
| BRPI0915231A2 (pt) * | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| US8846664B2 (en) | 2008-11-12 | 2014-09-30 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
| CN102232076B (zh) * | 2008-12-05 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪基脲激酶抑制剂 |
| UA103351C2 (uk) | 2008-12-05 | 2013-10-10 | Ебботт Леборетріз | ПОХІДНІ ТІЄНО[3,2-c]ПІРИДИНУ ЯК ІНГІБІТОРИ КІНАЗ ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ РАКУ |
| CA2744563A1 (en) * | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
| MY201120A (en) | 2009-02-25 | 2024-02-06 | Takeda Pharmaceuticals Co | Intermediates for use in a process of producing pyrrole compounds |
| US20110112101A1 (en) * | 2009-03-05 | 2011-05-12 | Sanofi-Aventis | Treatment for ocular-related disorders |
| EA022924B1 (ru) | 2009-04-03 | 2016-03-31 | Ф.Хоффманн-Ля Рош Аг | ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ |
| WO2010135411A2 (en) * | 2009-05-19 | 2010-11-25 | The Regents Of The University Of Colorado | Aurora-a copy number and sensitivity to inhibitors |
| WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| PH12015501678B1 (en) | 2009-06-17 | 2022-07-06 | Vertex Pharma | Inhibitors of influenza viruses replication |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| MA33975B1 (fr) | 2009-11-06 | 2013-02-01 | Plexxikon Inc | Composés et méthodes de modulation des kinases et leurs indications d'emploi |
| EP2338890A1 (en) | 2009-12-22 | 2011-06-29 | Bayer CropScience AG | 4,7-Diazaindole derivatives and their use as fungicides |
| PL2516434T3 (pl) | 2009-12-23 | 2015-11-30 | Takeda Pharmaceuticals Co | Skondensowane heteroaromatyczne pirolidynony jako inhibitory SYK |
| CA2787079A1 (en) * | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
| WO2011109932A1 (en) * | 2010-03-09 | 2011-09-15 | F.Hoffmann-La Roche Ag | Novel process for the manufacture of 5-halogenated-7-azaindoles |
| AU2011224484A1 (en) | 2010-03-10 | 2012-09-27 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| CA2798970A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives as syk and jak inhibitors |
| JP2013529204A (ja) * | 2010-05-20 | 2013-07-18 | エフ.ホフマン−ラ ロシュ アーゲー | ピロロ[2,3−b]ピラジン−7−カルボキサミド誘導体とJAK及びSYK及び阻害剤としてのそれらの使用 |
| MY161078A (en) | 2010-05-21 | 2017-04-14 | Incyte Holdings Corp | Topical formulation for a jak inhibitor |
| CA2800176C (en) * | 2010-05-24 | 2018-08-28 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
| WO2011153049A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| EP2635556B1 (en) * | 2010-11-01 | 2017-06-21 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
| EP2640723A1 (en) | 2010-11-19 | 2013-09-25 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| AU2011343642A1 (en) | 2010-12-16 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| JP5941069B2 (ja) | 2011-02-07 | 2016-06-29 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼ調節のための化合物および方法、ならびにそれに対する適応症 |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| EP2706852B1 (en) | 2011-05-10 | 2018-08-22 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| US9120785B2 (en) | 2011-05-10 | 2015-09-01 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as Syk inhibitors |
| WO2012154519A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| KR20140040819A (ko) | 2011-06-20 | 2014-04-03 | 인사이트 코포레이션 | Jak 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체 |
| US9056873B2 (en) | 2011-06-22 | 2015-06-16 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| CN103702998A (zh) | 2011-07-05 | 2014-04-02 | 沃泰克斯药物股份有限公司 | 生产氮杂吲哚类的方法和中间体 |
| WO2013012909A1 (en) | 2011-07-20 | 2013-01-24 | Abbott Laboratories | Kinase inhibitor with improved aqueous solubility |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| EP3473099A1 (en) | 2011-09-14 | 2019-04-24 | Samumed, LLC | Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2763974B1 (en) | 2011-10-05 | 2016-09-14 | Merck Sharp & Dohme Corp. | Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| WO2013052393A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| ES2984771T3 (es) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US9487504B2 (en) | 2012-06-20 | 2016-11-08 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
| EP2863915B1 (en) | 2012-06-22 | 2017-12-06 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2013192098A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| CN102718694B (zh) * | 2012-06-27 | 2014-04-02 | 上海大学 | 3-氰基取代吲哚化合物及其合成方法 |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9353066B2 (en) | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| EP2738172A1 (en) * | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9908867B2 (en) | 2013-01-08 | 2018-03-06 | Samumed, Llc | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| JP6397831B2 (ja) | 2013-03-06 | 2018-09-26 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤の製造方法及びその中間体 |
| SG11201507486SA (en) | 2013-03-13 | 2015-10-29 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
| TW201446763A (zh) * | 2013-03-14 | 2014-12-16 | Abbvie Inc | 吡咯并[2,3-b]吡啶cdk9激酶抑制劑 |
| CN105246890A (zh) * | 2013-03-14 | 2016-01-13 | 艾伯维公司 | 吡咯并[2,3-b]吡啶cdk9激酶抑制剂 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| KR20160045081A (ko) | 2013-08-07 | 2016-04-26 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
| JPWO2015029447A1 (ja) * | 2013-08-30 | 2017-03-02 | 興和株式会社 | 光学活性カルビノール化合物の製造方法 |
| JP6615755B2 (ja) | 2013-11-13 | 2019-12-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インフルエンザウイルスの複製の阻害剤 |
| AU2014348752C1 (en) | 2013-11-13 | 2019-11-21 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| SG11201704685TA (en) * | 2014-12-11 | 2017-07-28 | Beta Pharma Inc | Substituted 2-anilinopyrimidine derivatives as egfr modulators |
| EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| JP6914860B2 (ja) | 2015-07-01 | 2021-08-04 | カリフォルニア インスティチュート オブ テクノロジー | カチオン性粘液酸ポリマー系デリバリーシステム |
| US10206909B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10285982B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017023986A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10226453B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10166218B2 (en) | 2015-08-03 | 2019-01-01 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023987A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof |
| WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10231956B2 (en) | 2015-08-03 | 2019-03-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| WO2017023972A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| US10188634B2 (en) | 2015-08-03 | 2019-01-29 | Samumed, Llc | 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| WO2017024010A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| EP3362449B1 (en) * | 2015-10-13 | 2021-06-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
| WO2017079759A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
| US9938273B2 (en) * | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AR107030A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| EP3464266B1 (en) | 2016-06-01 | 2021-10-20 | Bayer Animal Health GmbH | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
| SG10201912248RA (en) | 2016-06-01 | 2020-02-27 | Samumed Llc | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide |
| CN106008306A (zh) * | 2016-06-28 | 2016-10-12 | 山东大学 | 取代吲哚类衍生物及其制备方法与应用 |
| AU2017345699A1 (en) | 2016-10-21 | 2019-05-16 | Samumed, Llc | Methods of using indazole-3-carboxamides and their use as Wnt/B-catenin signaling pathway inhibitors |
| WO2018085865A1 (en) | 2016-11-07 | 2018-05-11 | Samumed, Llc | Single-dose, ready-to-use injectable formulations |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| TW201904577A (zh) | 2017-06-16 | 2019-02-01 | 美商貝達醫藥公司 | N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| CN108358894B (zh) * | 2018-04-26 | 2021-05-07 | 四川大学 | 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用 |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| US20190381188A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
| MX2021007925A (es) | 2018-12-31 | 2021-10-26 | Biomea Fusion Llc | Inhibidores irreversibles de la interaccion menina-mll. |
| JP7532385B2 (ja) * | 2019-01-31 | 2024-08-13 | 杏林製薬株式会社 | 15-pgdh阻害薬 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN111171001B (zh) * | 2019-05-16 | 2022-04-29 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的结晶方法 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US20230116201A1 (en) * | 2020-01-30 | 2023-04-13 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法 |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為fgfr抑制劑之三環雜環 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CA3228627A1 (en) | 2021-08-11 | 2023-02-16 | Thomas Butler | Covalent inhibitors of menin-mll interaction for diabetes mellitus |
| CN119816500A (zh) | 2021-08-20 | 2025-04-11 | 拜欧米富士恩公司 | 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式 |
| EP4561567A2 (en) * | 2022-07-28 | 2025-06-04 | University of Maryland, Baltimore | Inhibitors of pde11a4 and methods of using same |
| WO2024155719A1 (en) | 2023-01-18 | 2024-07-25 | Biomea Fusion, Inc. | Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2- pyridinecarboxamide as a covalentinhibitor of menin-mll interaction |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB966264A (en) | 1961-08-31 | 1964-08-06 | Distillers Co Yeast Ltd | Production of alkyl pyridines |
| GB1141949A (en) * | 1966-02-23 | 1969-02-05 | Sterling Drug Inc | 7-azaindole derivatives |
| US3992392A (en) * | 1973-04-27 | 1976-11-16 | The Ohio State University Research Foundation | Synthesis of indoles from anilines and intermediates therein |
| EP0405602A1 (en) | 1989-06-30 | 1991-01-02 | Laboratorios Vinas S.A. | New Zinc derivatives of anti-inflammatory drugs having improved therapeutic activity |
| SE9100920D0 (sv) | 1991-03-27 | 1991-03-27 | Astra Ab | New active compounds |
| FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
| JP3119758B2 (ja) | 1993-02-24 | 2000-12-25 | 日清製粉株式会社 | 7−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬 |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| DE4435477A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
| US5589482A (en) | 1994-12-14 | 1996-12-31 | Pfizer Inc. | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia |
| GB2298199A (en) | 1995-02-21 | 1996-08-28 | Merck Sharp & Dohme | Synthesis of azaindoles |
| FR2732969B1 (fr) | 1995-04-14 | 1997-05-16 | Adir | Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| DE59704157D1 (de) | 1996-01-30 | 2001-09-06 | Ciba Sc Holding Ag | Polymerisierbare Diketopyrrolopyrrole und damit hergestellte Polymere |
| WO1998002437A1 (en) * | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| US6184235B1 (en) | 1996-08-14 | 2001-02-06 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as MCP-1 antagonists |
| US6180643B1 (en) | 1996-11-19 | 2001-01-30 | Amgen Inc. | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
| US6312835B1 (en) | 1997-02-13 | 2001-11-06 | Queen's University At Kingston | Luminescent compounds and methods of making and using same |
| WO1998047899A1 (en) * | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
| PL340412A1 (en) * | 1997-10-20 | 2001-01-29 | Hoffmann La Roche | Bicyclic kinase inhibitors |
| WO1999045016A2 (en) | 1998-03-06 | 1999-09-10 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
| WO1999051595A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| JP2002510630A (ja) | 1998-04-02 | 2002-04-09 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬 |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| AU3368299A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| EP1067930A4 (en) | 1998-04-02 | 2002-09-18 | Merck & Co Inc | GONADOLIBER'S ANTAGONISTS |
| CA2326140A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| CA2325995A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| JP2002514635A (ja) | 1998-05-12 | 2002-05-21 | アメリカン・ホーム・プロダクツ・コーポレイション | インスリン耐性および高血糖の処置に有用なビフェニルオキソ−酢酸 |
| ATE482945T1 (de) * | 1998-05-26 | 2010-10-15 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| SE510289C2 (sv) | 1998-06-09 | 1999-05-10 | Car O Liner Ab | Fastspänningsanordning för fordon vid en riktbänk |
| HK1039325B (en) * | 1998-09-18 | 2006-02-24 | Abbott Gmbh & Co. Kg | 4-aminopyrrolopyrimidines as kinase inhibitors |
| CN1173938C (zh) | 1998-12-31 | 2004-11-03 | 阿温蒂斯药物公司 | 未保护的β-氨基酯化合物的α-取代 |
| DE60007310D1 (de) | 1999-06-04 | 2004-01-29 | Elan Pharma Int Ltd | Zusammensetzungen und methoden zur verhinderung des zelltods |
| US6207699B1 (en) | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| DE19951360A1 (de) | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| CN1615873A (zh) * | 1999-12-24 | 2005-05-18 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US20030004174A9 (en) | 2000-02-17 | 2003-01-02 | Armistead David M. | Kinase inhibitors |
| DE10009000A1 (de) | 2000-02-25 | 2001-08-30 | Basf Ag | Verfahren zur Herstellung substituierter Indole |
| CA2400923A1 (en) | 2000-02-25 | 2001-08-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| GB0007657D0 (en) | 2000-03-29 | 2000-05-17 | Celltech Therapeutics Ltd | Chemical compounds |
| BR0110302A (pt) | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| WO2001096336A2 (en) * | 2000-06-14 | 2001-12-20 | Warner-Lambert Company | 6,5-fused bicyclic heterocycles |
| US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| EP1324985A4 (en) | 2000-10-02 | 2004-10-06 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASE INHIBITORS |
| GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
-
2001
- 2001-06-21 GB GBGB0115109.1A patent/GB0115109D0/en not_active Ceased
-
2002
- 2002-06-20 BR BR0210507-1A patent/BR0210507A/pt not_active IP Right Cessation
- 2002-06-20 TW TW091113956A patent/TWI334417B/zh not_active IP Right Cessation
- 2002-06-20 JP JP2003507091A patent/JP4409938B2/ja not_active Expired - Fee Related
- 2002-06-20 YU YU96903A patent/YU96903A/sh unknown
- 2002-06-20 WO PCT/GB2002/002799 patent/WO2003000688A1/en not_active Ceased
- 2002-06-20 EP EP09171579A patent/EP2233486A1/en not_active Withdrawn
- 2002-06-20 UA UA2004010424A patent/UA85660C2/ru unknown
- 2002-06-20 HR HR20031069A patent/HRP20031069A2/hr not_active Application Discontinuation
- 2002-06-20 PL PL02365067A patent/PL365067A1/xx not_active Application Discontinuation
- 2002-06-20 SK SK1590-2003A patent/SK15902003A3/sk not_active Application Discontinuation
- 2002-06-20 HU HU0400247A patent/HUP0400247A2/hu unknown
- 2002-06-20 IL IL15944502A patent/IL159445A0/xx unknown
- 2002-06-20 RU RU2004101408/04A patent/RU2326880C2/ru not_active IP Right Cessation
- 2002-06-20 AP APAP/P/2003/002940A patent/AP1739A/en active
- 2002-06-20 OA OA1200300343A patent/OA12637A/en unknown
- 2002-06-20 KR KR1020097006249A patent/KR100977344B1/ko not_active Expired - Fee Related
- 2002-06-20 JO JO200264A patent/JO2327B1/en active
- 2002-06-20 CA CA2451678A patent/CA2451678C/en not_active Expired - Fee Related
- 2002-06-20 NZ NZ545741A patent/NZ545741A/en unknown
- 2002-06-20 KR KR1020037016763A patent/KR100915289B1/ko not_active Expired - Fee Related
- 2002-06-20 EE EEP200400015A patent/EE200400015A/xx unknown
- 2002-06-20 NZ NZ529205A patent/NZ529205A/en unknown
- 2002-06-20 CN CNB028124766A patent/CN100509811C/zh not_active Expired - Fee Related
- 2002-06-20 EP EP02730531A patent/EP1397360A1/en not_active Withdrawn
- 2002-06-20 CZ CZ20033444A patent/CZ20033444A3/cs unknown
- 2002-06-20 SI SI200220015A patent/SI21462A/sl not_active IP Right Cessation
- 2002-06-21 UY UY27350A patent/UY27350A1/es unknown
- 2002-06-21 AR ARP020102348A patent/AR036106A1/es unknown
- 2002-06-21 MY MYPI20022345A patent/MY137099A/en unknown
- 2002-06-21 PA PA20028548701A patent/PA8548701A1/es unknown
- 2002-06-21 US US10/177,804 patent/US6897207B2/en not_active Expired - Fee Related
- 2002-06-21 HN HN2002000154A patent/HN2002000154A/es unknown
- 2002-06-21 PE PE2002000541A patent/PE20030155A1/es not_active Application Discontinuation
-
2003
- 2003-07-08 TN TNPCT/GB2002/002799A patent/TNSN03110A1/en unknown
- 2003-12-09 NO NO20035476A patent/NO20035476D0/no unknown
- 2003-12-11 ZA ZA200309468A patent/ZA200309648B/xx unknown
- 2003-12-18 EC EC2003004914A patent/ECSP034914A/es unknown
- 2003-12-19 BG BG108481A patent/BG108481A/bg unknown
- 2003-12-19 MA MA27453A patent/MA27043A1/fr unknown
-
2004
- 2004-11-23 US US10/995,103 patent/US7943616B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4409938B2 (ja) | アザインドール | |
| JP5436507B2 (ja) | アザインドール | |
| JP4871474B2 (ja) | アザインドール | |
| AU2002302849A1 (en) | Azaindoles | |
| AU2009200024A1 (en) | Azaindoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050615 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050615 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090331 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090630 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090722 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091027 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091112 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121120 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |